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Chapter 1
Introduction
Management of Patients with 
familial hypercholesterolemia:
cure and care
Cardiovascular disease and risk factors
Cardiovascular disease (CVD) is the leading cause of death in middle aged men
and women globally 1. The process of atherosclerosis starts already in childhood
and during the life course various risk factors contribute to the further develop-
ment of atherosclerosis, eventually leading to CVD later in life 2. Therefore CVD
is an outcome of an interplay between long-standing risk factors. Traditional
risk factors are smoking, physical inactivity and unhealthy diet leading to meta-
bolic changes such as overweight or obesity, hypertension, diabetes mellitus
and hypercholesterolemia 3. Hypercholesterolemia has been identified as one
of the major risk factors for developing and progression of atherosclerosis. 
This thesis focuses on diagnosis, risk prediction and management of familial
 hypercholesterolemia (FH), the most common monogenetic disorder causing
hypercholesterolemia. 
Introduction to familial hypercholesterolemia
FH is an autosomal dominant disorder of the lipid metabolism with an estimated
prevalence of 1:244 in the Netherlands 4. FH is caused by loss of function mu-
tations in genes encoding for the low-density lipoprotein-receptor (LDLR),
apolipoprotein B (APOB) and gain of function mutations in the PCSK9 gene.
The diagnosis FH can be made genetically by DNA analysis or clinically by using
the Dutch Lipid Clinic Network Criteria (table) 5.
FH is associated with a severe risk of premature CVD 6, 7. Untreated, the risk of
CVD in men and women with FH is 50% before the age of 50 years and 30%
 before the age of 60 years respectively 8.
In the Netherlands, a nationwide population cascade screening program in
 families with a pathogenic variant causing FH has been carried out between
2001-2013. Of the estimated 70.000 people with FH in our country, almost 30.000
have been diagnosed 9. The majority of these FH patients were identified
through cascade screening, based on one index patient of a family. 
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Table: Dutch Lipid Network Criteria for FH 10
Family history points
First-degree relative with premature coronary and/or vascular 
disease (men ≤55 years, women ≤60 years), OR first-degree
relative with known LDL-cholesterol ≥95th percentile for age 
and sex 1
First-degree relative with tendon xanthomata and/or arcus
cornealis, OR
Children aged ≤18 years with known LDL-cholesterol ≥95th 
percentile for age and sex 2
Clinical history
Patient with premature coronary artery disease (age as above) 2
Patient with premature cerebral or peripheral vascular disease 
(age as above) 1
Physical examination
Tendon xanthomas 6
Arcus cornealis at age ≤45 years 4
LDL-Cholesterol levels mmol/L (mg/dL)
LDL-C ≥8.5 (330) 8
LDL-C 6.5 - 8.4 (250 - 329) 5
LDL-C 5.0 - 6.4 (190 - 249) 3
LDL-C 4.0 - 4.9 (155 - 189) 1
DNA Analysis 
Functional mutation LDLR, APOB and PCSK9 8
Diagnosis FH
Definite FH: >8 points.
Probable FH: 6-8 points.
Possible FH: 3-5 points.
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Management of familial hypercholesterolemia
Management of patients with FH consists of a combination of lifestyle modifi-
cation and medical treatment.
Treatment by lifestyle modification
Classical vascular risk factors such as smoking, overweight, inactivity, hyperten-
sion and diabetes mellitus are similar to non-FH individuals associated with an
increased CVD risk in FH patients 11, 12. Therefore guidelines highly recommend
lifestyle modification 13. Although no trials have been performed to study the
effect of lifestyle intervention specifically in FH patients, there is no reason to
assume that the results of lifestyle intervention are different for people with or
without FH. Lifestyle modification; such as smoking cessation, weight reduction,
sufficient physical exercise and a healthy diet can play an important role in the
delay of progression of atherosclerosis in patients with an increased CVD risk
14. However it is well established that the success of long-term lifestyle modifi-
cation is limited. Therefore, the most successful approach of CVD risk preven-
tion is to promote a healthy lifestyle from early age onwards ideally starting in
children with FH. But even with a healthy lifestyle, the cardiovascular risk of FH
is still elevated compared to non-FH subjects 15.
Current medical treatment
The cornerstone of medical treatment is a timely start with lipid-lowering the -
rapy (LLT). HMG-coenzyme A inhibitors also known as statins were first intro-
duced in the 1976 and received wide publicity since the Scandinavian
Simvastatin Survival Study Group trial showed that statins are associated with
LDL-C reduction leading to decreased CVD events 16, 17. Statin treatment can
be considered as causal therapy for FH patients. During previous decades more
and more potent statins were developed with increased LDL-C lowering poten-
tial. Numerous randomized clinical trials showed that statins lower CVD risk and
also demonstrated that CVD risk was inversely related to LDL-C levels. The
 efficacy of statin treatment in FH patients without CVD is much higher than ob-
served in most large primary prevention trials; 76% versus approximately 37%
CVD risk reduction, respectively 18. In FH patients using statins, the addition of
the Niemann-Pick C1-like 1 receptor antagonist ezetimibe led to LDL-C reduc-
tion but not to improvement of subclinical atherosclerosis represented by intima
media thickness 19. Later on the Improved Reduction of Outcomes: Vytorin
 Efficacy International Trial (IMPROVE-IT) showed that patients with CVD who
were randomized to ezetimibe in addition to statins, developed less “hard-end-
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points” namely cardiovascular events compared to patients who used statin
monotherapy 20. Thereby proving that LDL-C reduction is associated with de-
crease in cardiovascular events, independent of how this is achieved. However
even despite optimal current LLT some FH patients still  develop CVD.
New lipid lowering therapy
Recently Proprotein convertase subtilisin / Kexin (PCSK9) inhibitors, a new class
of LLT have been developed. Randomized controlled trials, demonstrated that
these monoclonal antibodies can further lower LDL-C levels up to 60% 21, 22.
This new drug has potentially advantages being highly effective and has a
favourable safety profile. However, it is important to ensure that data from clin-
ical trials apply to real-life settings as well, especially when it concerns long term
safety. Therefore “real life data” are needed to improve the applicability of the
trial evidence to daily practice.
Adherence of medication
Adherence is defined as ‘the extent to which patients follow the recommenda-
tions by their healthcare professional’ 23. Non-adherence to prescribed drug
regimens is a pervasive medical problem. In general, adherence rates are low
in patients with chronic diseases. Non-adherence or partial adherence is a prob-
lem in patients with CVD, as these patients have significant higher risk of car-
diovascular events compared to patients who are fully adherent 24. Many
different factors such as primary prevention, side effects and low level of edu-
cation have been associated with poor adherence to medication. In patients
with FH adherence is a continuous challenge as they have to adhere to life-long
medication without short-term benefit. Only a minority of FH patients treated
with lipid-lowering medication achieve their LDL-C treatment goal 25, however
it is not known whether this poor result is attributable to poor adherence. More-
over, it is unknown which factors are associated with adherence in the FH pop-
ulation. Potentially there is much to be gained by improving adherence. A
number of possibilities can contribute to adherence such as motivational inter-
viewing, follow-up by the Medication Electronic Monitoring System (MEMS) and
strategies for enhancing self-efficacy 26-28. However, it all starts with recognizing
non-adherence as a problem. 
The role of the nurse practitioner
FH patients have a chronic disorder, they are advised to use lifelong medication
and to take lifestyle changes into account. Maintaining a healthy lifestyle con-
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sisting of non-smoking, a healthy diet, sufficient physical exercise in combination
with an adequate medication intake, are considered essential components of
self-management 29. Improving self-management by optimizing risk factors
modification contribute to successful CVD prevention 30, 31. Nurse practitioners
(NP) are educated in providing tools for promotion of self-management and
self-efficacy as well as medical treatment combining both care and cure. In ad-
dition to providing education about FH, cardiovascular risk factors and coun-
selling in health behaviour, a NP can prescribe and modify medication but also
offer patient education for example how to use new medication such as PCSK9
inhibitors. Therefore the integrated approach of the NP can have an important
place in the treatment of FH patients. 
Special populations in clinical management of familial hypercholesterolemia 
Children with familial hypercholesterolemia 
In children with FH, the process of atherosclerosis and elevated LDL-C levels
starts early in childhood. Potentially individuals with FH can have a normal life
expectancy if treatment starts early. Recommendations to commence treatment
with low doses of statin and a healthy lifestyle at young age are recommended
in the European consensus for management of children with FH 32. Therefore
identification of these young subjects through active cascade screening is a
 necessity.
Women with familial hypercholesterolemia
Recently more awareness and attention has been paid to gender-specific med-
icine. Traditionally men were the standard and research including drug trials
were confined to men. Little is known about gender-differences in the manage-
ment of FH patients. In general statins have a similar efficacy in men and women,
however it is unclear whether women experience more statin associated side
effects 33, 34. Therefore it is essential to investigate potential gender differences
in management of FH patients and the factors contributing to the treatment
among women and men.
Aims and outline of thesis 
This thesis addresses gaps in knowledge in diagnosis and management of pa-
tients with FH. The aim of these studies is not only to describe the current status
but also provide clinical tools how diagnosis, risk prediction and management
can be further improved for these patients in clinical practice.
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The thesis consists of studies dedicated to the diagnosis and risk prediction of
patients with FH (chapter 2,3,4) and the second part (chapter 5,6,7) comprises
studies on the management of patients with FH.
In chapter 2 we investigate issues concerning dyslipidemia testing in general
such as why should lipids be tested, in whom, and when should they be tested. 
In chapter 3 we investigate the success of our cascade screening program by
assessing whether children with FH have been identified through cascade
screening or due to CVD in the FH parent.
In chapter 4 we assess the residual risk of cardiovascular events in heterozygous
FH patients who use long-term lipid lowering therapy.
Chapter 5 presents a prediction model for identification of FH patients, who
are non-adherent to statin therapy.
In chapter 6 we study the differences in the management of FH patients be-
tween men and women.
Chapter 7 describes the first experiences with Proprotein convertase subtilisin/
Kexin 9 (PCSK9) inhibition in patients with FH outside clinical trials.
This is followed by the general discussion and summary.
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Chapter 2
Dyslipidemia testing: 
Why, for whom and when
J.M.H. Galema-Boers, J.E. Roeters van Lennep
Maturitas. 2015 Aug;81(4):442-5. pii: S0378-5122(15)00698-2.
doi: 10.1016/j.maturitas.2015.05.012.
Abstract
Dyslipidemia is a major risk factor for cardiovascular disease. This review ad-
dresses why, who and when to test for dyslipidemia. The essence why to test
lipids is that those individuals recognized to potentially benefit from cardiovas-
cular risk prevention, have a complete cardiovascular risk assessment. Who and
when to test lipids differs among the major European, English and American
guidelines regarding the recommended age and approach. It is important to
note that the threshold and the frequency in whom to perform risk assessment
is not established. Most important in decisions concerning lipid testing is com-
munication and to involve individual circumstances.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in middle-aged and
older adults globally 1. CVD can be considered to be the outcome of an inter-
play between long-standing risk factors 2. One of the most indisputably estab-
lished risk factors for developing and progression of atherosclerosis is
dyslipidemia 3, 4. Dyslipidemia covers a broad spectrum of lipid abnormalities,
including elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C)
and triglyceride levels and low high-density lipoprotein cholesterol (HDL-C)
 levels which have been associated with increased risk of CVD risk. For patients
with CVD, it is generally agreed upon by all guidelines that lipid testing -at least
at baseline- is mandatory. However, in people without CVD this is not as well-
defined. 
This review will focus on lipid testing in primary cardiovascular prevention and
will discuss the following questions concerning dyslipidemia testing: why should
we test lipids? In whom should we test lipids and when should we test them? 
Why test lipids?
The starting point of lipid testing should be the decision to perform a cardio-
vascular risk assessment of which testing lipids is one component. It is essential
to first determine whether a certain individual is likely to benefit from CVD risk
intervention. Factors which affect the judgement whether or not assessing car-
diovascular risk is appropriate or not are life expectancy, time to benefit and
functional status. The results of cardiovascular risk assessment -including lipid
levels- can be used to identify those who are likely to benefit from specific in-
terventions and may support the dialogue between a health care professional
and the patient if and how to modify cardiovascular risk. It is important to em-
phasize that the main goal to test lipids should be broader than to identify those
who qualify for lipid-lowering therapy but also include lifestyle modification 5-8. 
In the case treatment is needed, safe and effective drug treatment is available.
Especially statin therapy has been shown to very effectively lower CVD in both
primary and secondary prevention 9-11.
Therefore, the core why to test lipids is that those individuals recognized to
 potentially benefit from cardiovascular risk prevention, have a complete cardio-
vascular risk assessment.
Who to test?
The opinion for who prevention of CVD is efficacious can be captured by two
main approaches: the population-based strategy and the high risk strategy. Both
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lines are meaningful and complement each other. The population-based stra -
tegy aims to decrease the overall risk profile in the general population. This can
be accomplished by preventive measures on a large scale for example if butter
would be replaced by margarine in the supermarket. On population level this
could lead to lower cholesterol levels and subsequent lower CVD. However, for
the individual the gain will be small, hence this is known as the prevention par-
adox 12. 
The high risk approach focuses on identifying individuals at elevated risk of car-
diovascular disease. The decision to screen for lipid levels is based on the proba-
bility that the results might lead to an overall risk of CVD high enough for
intervention such as lipid-lowering therapy. This approach aimed to target the risk
of the individual, is considered a more cost-effective use of limited resources in
comparison with mass screening 12. Targeted cardiovascular screening can identify
up to 84% of high-risk individuals, which can be considered a good yield 13.
Who should we test according the guidelines?
Among the guidelines no uniformity exists in the recommendations in whom to
test lipids. We summarized and compared three high risk strategy guidelines
for prevention of CVD in primary cardiovascular prevention setting (table 1).
The objective of all these guidelines is to provide recommendations how to pre-
vent (recurrent) CVD by estimating the probability of the 10-years or life-time
risk of a first cardiovascular event in individuals. The high risk strategy guidelines
use risk estimation systems based on different longitudinal cohort studies of
several countries. Finally, we describe the American Heart Association (AHA)
2020 impact goals, a population-based strategy. 
The latest version of the Systematic Coronary Risk Evaluation (SCORE) is used
in the ESC/EAS guideline 2012. Separate charts are used depending on sex,
smoking status, age groups, hypertension and total cholesterol/HDL-C ratio.
CVD screening including lipid testing is recommended in all men of ≥40 years,
and women ≥50 years or if postmenopausal, particularly in the presence of other
risk factors based on the SCORE estimation. Special high risk groups such as
those with chronic kidney disease (CKD), familial hypercholesterolemia (FH) and
type 1 or type 2 diabetes mellitus (DM) with micro-albuminuria, qualify for lipid
screening irrespective of age 5.
The Joint British Societies (JBS3) recommendations of CVD risk assessment and
modification of blood lipids are closely linked to National Institute for Health
and Care Excellence (NICE) 6, 8. They published the most recent guideline in
2014. Their QRISK2 risk calculator is based on risk factors such as age, sex, cho-
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lesterol/HDL ratio, blood pressure and/or use antihypertensive medication, DM,
smoking status, ethnicity, region of United Kingdom, family history of coronary
heart disease (CHD) before age 60, deprivation, body mass index (BMI), rheuma-
toid arthritis (RA), CKD, and atrial fibrillation. These guidelines do not only focus
on identifying and treating individuals with >10% CVD risk within 10 year but
also incorporate lifetime risk assessment aiming at individuals who will have a
potential benefit of lowering risk factors. In the United Kingdom adults 40 to 74
years are invited for the National Health Service (NHS) Health Check pro-
gramme by general practices and other health care providers to have their lipids
tested. An exception exists for those with (suspected) FH for whom lipid testing
is advised at the age of 10 years or as soon as possible thereafter 14.
In 2013 the American College of Cardiology (ACC)/AHA guideline developed
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Who
Men ≥40 years, women≥50 years or 
postmenopausal, particularly in the presence 
of other risk factors
Early lipid screening irrespective of age for;
• Patients with CKD
• Chronic inflammatory disease
• Family history of FH and/or CVD
• Severe hypertension
• Patients with DM and organ damage
• Smoking and/or BMI ≥30 kg/m2
All adults aged ≥40 years 
Special groups;
• Adults of any age with a family history of 
premature CVD (men ≤55 years/women 
≤60 years).
• All individuals with a first degree relative 
with FH.
• Adults with DM, RA, CKD and hypertension. 
• All adults aged ≥20 years
Special groups:
• LDL-C ≥ 90 mg/dl
• DM aged 40-75 years and LDL 70-189 mg/dl
• Without DM aged 40-75 years with 
10-year ASCVD risk ≥7.5%
• Children and first degree relatives of patients 
≥190 mg/dl screening for FH
When
During a consultation
• Before starting lipid lowering therapy; 
2 measurements should be made 1-12 weeks 
interval
• 8 (±4) weeks after starting drug treatment
• Once a year when a patient has reached 
target or optimal cholesterol
• More frequent when there is an adherence 
problem
Every 5 years
• Following lifestyle modification
• Once a year when a patient has reached
target or optimal cholesterol
Every 5 years in individuals 40-75 years old 
without CVD or DM and with a LDL-C 
70-189 mg/dl
• Before starting lipid lowering therapy; 
2 measurements should be made 1 -12 weeks 
interval
• 4-12 weeks after starting drug treatment 
• Every 3-12 months as clinically indicated
• Annually in FH patients
Lipid testing
Risk based guidelines
ESC/EAS 5
NICE and JBS3 6,8
ACC/AHA 7
Why
• Preventing CVD
• Lowering CVD risk
• Preventing CVD
• Lowering CVD risk
• Preventing CVD
• Lowering CVD risk
ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; NICE, National Institute for Health and Care Excellence, JBS3,
Joint British Societies; ACC/AHA, American College of Cardiology/American Heart Association; CVD, cardiovascular disease; FH, familial
hypercholesterolemia; DM, diabetes mellitus; RA, rheumatoid arthritis; CKD, chronic kidney disease; LDL-C, low density lipoprotein-cholesterol;
BMI, body mass index; ASCVD, atherosclerotic cardiovascular disease.
Table 1. Recommendation of lipid testing regarding primary prevention 
according to cardiovascular risk prevention guidelines.
a new atherosclerotic cardiovascular disease (ASCVD) risk estimator, based on
age, sex, race, blood pressure and/or use antihypertensive medication, DM,
smoking status and cholesterol/HDL ratio to estimate the 10-year CVD risk. Con-
trary to the previous guidelines, the ACC/AHA guideline recommends lipids to
be measured as early as 20 years of age in all individuals, with special emphasis
on those whom most likely benefit from statins such as those aged 40-75 years
with either DM or with a 10 years risk ≥7.5% and a LDL-C 70-189 mg/dL. Indi-
viduals with a LDL-C ≥190 mg/dl and their first degree relatives are advised to
have their lipids tested as part of FH screening without a lower threshold of age
7, 15. 
In the United States the AHA has initiated a shift from secondary and primary
prevention towards primordial prevention by a comprehensive public health
strategy to prevent cardiovascular diseases emphasized by lifestyle modification
and supported by cost-savings data 16, 17. The 2020 impact goals developed by
the AHA deliberately chooses to emphasize the development of healthy lifestyle
beginning in childhood and adolescence, continuing throughout life course.
The aim is to lower risk and burden of CVD by promoting cardiovascular health.
To measure cardiovascular health the AHA has developed a cardiovascular
health score based on three health factors: blood pressure, fasting glucose and
total cholesterol and four health behaviors; smoking status, physical activity,
healthy diet and BMI. Lipid testing throughout the life course is advised for
everybody including children 18.
In conclusion, the recommendation in whom to test lipids in primary prevention
setting, differs among the aforementioned high-risk guidelines regarding age
and particular population whereas the population-based strategy advocates
lipid testing for all.
When to screen 
How often CVD screening, including lipid testing, should be repeated in indi-
viduals without CVD, is not described in every guideline. The ESC/EAS guide-
lines designate the general practitioner as central health care provider to initiate
and coordinate lipid testing in the process of CVD prevention and does not
specify an interval when retesting lipids is advised unless lipid-lowering treat-
ment is initiated.
The NICE guideline suggests to offer people the opportunity to recalculate their
CVD risk after lifestyle modification. How active or intensive the approach for
risk assessment will be, always depends on the health care provider and the
motivation of the patient. A confident patient-clinician relation and awareness
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of risk behaviour is essential to achieve lifestyle changes 19. 
According the ACC/AHA guidelines the estimated 10-year ASCVD can be
 recalculated every 5 years in individuals 40-75 years without ASCVD or DM and
with LDL-C 70-189 mg/dL. Longer intervals are recommended for those without
an increased risk and normal lipid levels 7, 15. Hence, recommendations regard-
ing the frequency of lipid testing vary among guidelines.
Conclusion
Before lipid testing every clinician should ask the question: What do the results
mean to my patient? A systematic risk stratification to identify those at the high-
est risk is required. European, British and American guidelines are all based on
a risk calculator but differ in their recommendations concerning lipid testing.
What they have in common is that they advocate an integrated approach with
the engagement of the patient as a partner in CVD prevention. 
Nonetheless, despite all guidelines, in the end decisions concerning lipid test-
ing are about communication with the patient involving individual circumstances
including why, who and when.
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Abstract 
Purpose
This study assesses the success of the recently terminated Dutch nationwide
cascade screening by examining whether children with familial hypercholes-
terolemia (FH) were identified through family screening or due to cardiovascular
(CVD) events in the FH parent.
Methods
We collected clinical information of all children (0-18 years) with FH with a path-
ogenic variant at our outpatient lipid clinic between 1992 and 2014 and their
FH parents and FH grandparents. 
Results
We analysed 292 FH children from 205 parents with FH. A history of premature
CVD was present in 20% of the parents (29% of the fathers, 9% of the mothers)
and 49% of the FH grandparents.
Conclusion
The fact that CVD is still a presenting event of FH in especially fathers shows
that nationwide screening might have been terminated too early. Therefore we
recommend to proceed the cascade screening.
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Introduction
Familial hypercholesterolemia (FH) is a disorder of lipid metabolism associated
with a severe risk of cardiovascular disease (CVD) 1, 2. Effective CVD prevention
is available, consisting of lifestyle changes and lifelong statin treatment 3, 4. Re-
cent data showed that FH is more prevalent in the Netherlands than previously
assumed: these data suggest that the prevalence might be as high as 1:244 5.
In The Netherlands a well-known nationwide cascade screening in families with
a pathogenic variant causing FH has been carried out over the last 15 years.
This program, supported by the Dutch Ministry of Public Health, Welfare and
Sport, involved genetic fieldworkers who visited relatives at home, and collected
medical information and blood samples. Due to end of funding, this national
cascade screening program has terminated at the end of 2013. At that moment
>28.000 people with FH were identified, 42% of the expected number of FH
patients in The Netherlands 6. The aim of the program is that FH patients are
identified through cascade family screening rather than as a consequence of
CVD bringing them into clinical attention. A method to assess the success of
our cascade screening program is to study whether children with FH have been
identified through cascade screening or due to CVD in the parents. The aim of
this study was to identify how many of the children treated at our clinic were
 referred because of a parent with CVD. 
Patients and methods
Participants
All consecutive children with FH who visited the outpatient lipid clinics of the
Erasmus MC or Sophia Children Hospital The Netherlands for the first time with
an age ≤18 years, between April 1993 and November 2014 were considered el-
igible for inclusion in this study. The diagnosis FH was based on identification
of a FH pathogenic variant in the LDL-receptor (LDLR) gene or the Apolipopro-
tein B (APOB) gene. The variants in patients were reviewed by a specialist of
the laboratory that identified and characterized these variants (dr. ir. J.
 Defesche). All variants presented in this study were pathogenic variants, either
because they have been published as pathogenic by in vitro activity assays or
by co-segregation in families. Children diagnosed with FH based on clinical
grounds were excluded. 
The Medical Ethical Review Committee of the Erasmus MC, The Netherlands,
considered the protocol non-Medical Research Involving Human Subjects Act
(WMO) therefore review of the protocol was waved.
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Study design
FH patients are treated by the Cardiovascular Genetics (CVG) team consisting
of a lipidologist, a nurse practitioner and a research nurse specialized in collect-
ing pedigree data. Parents are advised to bring their children from the age of
10 years for follow-up. Children and parents with FH receive regular tailored
 education about their disease, lifestyle advices, benefits of using statins and the
effect of treatment on lipid profiles. 
Clinical data such as medication, LDLR or APOB gene pathogenic variant,
plasma lipid values (triglycerides, total, LDL-cholesterol (LDL-C) and HDL-cho-
lesterol (HDL-C), family history of cardiovascular disease and general character-
istics such as age, sex and date of first visit were collected from the childrens’
files. Genetic testing of FH pathogenic variants of all the children was performed
by the laboratory of cardiovascular genetics in the Academic Medical Centre,
Amsterdam 7.
Pedigree data and clinical data of the FH parents and grandparents of all
 children were collected. Premature CVD was defined as one of the following:
myocardial infarction, proven angina, Coronary Artery Bypass Grafting (CABG)
or Percutaneous Coronary Intervention, stroke and peripheral arterial disease
in men <55 years and women <60 years 8. These events were assessed from the
patients' medical records and adjudicated by the study team. 
Statistics
All data were analysed anonymously using SPSS (version 21.0). Chi-square tests
to assess differences in proportions, and the student t-test (since the data were
normally distributed) to assess differences in means were used. The values are
presented as mean±Standard Deviation (S.D.), unless otherwise specified.
 Dichotomous variables are presented as numbers and percentages. Statistical
significance was defined as P ≤0.05. For the analysis per parent we selected the
oldest child.
Results 
A total of 292 of 308 consecutive FH children were included in this study. Sixteen
subjects were excluded because of FH on clinical grounds. Of the 292 children
of 205 parents with FH, 154 were girls. Most children (57%) inherited FH from
their father. The majority was Caucasian (94%). Fifty-nine different pathogenic
variants were identified. The p.Trp44* pathogenic variant of the LDLR gene was
the most prevalent (11%). An APOB pathogenic variant was detected in 8% of
the subjects. The average age at first visit to the lipid clinic was 10.6±4.3 years
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(range: 0.2-18.0 years). Untreated lipid levels were known of the majority of the
children (92%). They had an untreated total cholesterol level of 7.1±1.5 mmol/l
and an LDL-C level of 5.4±1.4 mmol/l. Sixty-three percent of the FH children
started with a statin after their first visit; 95% of the FH children used a statin at
a certain point during follow-up. The mean age of starting statin treatment was
13.6±3.1 years.
Table 1. General characteristics of children with FH
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Girls, n (%)
Maternal inheritance, n (%)
Paternal inheritance, n (%)
Dutch Ethnicity, n (%)
Age (yrs) first visit (mean±SD)
Age (yrs) started statin (mean±SD)
DNA pathogenic variants, n (%)
LDL receptor pathogenic variant
• p.Trp44* 
• c.313+1G>A
• c.191-2A>G
Apo B gene pathogenic variant
Untreated lipid values 1st visit, 
mean±SD
• Total cholesterol (mmol/l) 
• LDL-C (mmol/l) 
• HDL-C (mmol/l)
• Triglyceride (mmol/l) 
Cholesterol lowering Medication
Medication at 1st visit
Started medication after 1st visit
No medication at all
Children
with
FH
(n=292)
154 (53)
125 (43)
167 (57)
273 (94)
10.6±4.3
13.6±3.1
59 (100)
269 (92)
32 (11)
27 (9.2)
24 (8.2)
23 (7.9)
7.1±1.5
5.4±1.4
1.3±0.3
1.0±0.5
2   (1)
180 (63)
90  (31)
Parent 
with
CVD 
(n=41)
12.1±3.9
13.9±2.6
Parent 
without 
CVD
(n=164)
11.1±4.3
14.2±3.2
p-value
0.39
0.23
FH= familial hypercholesterolemia, LDL-C= low density lipoprotein cholesterol, 
HDL-C= high density lipoprotein cholesterol, CVD= cardiovascular disease
CVD in parents of FH children
A history of CVD was present in 20% (n=41) of the FH parents; 29% (n=33) of
the fathers and 9% (n=8) of the mothers. With one exception, all suffered from
premature CVD. The mean age of the first event was of 41±8.5 years. In five of
these parents (all men), CVD was fatal. Of the grandparents with FH, 49% had
a history of CVD, the mean age of their first event was 51±11.1 years. It was not
possible to analyse differences in percentage of FH parents with CVD  between
the first decade (1993-2003) and the second (2004-2014) because of the low
number of children visiting the out-patient clinic in the first decade.
Children with a parent without CVD tended to visit the lipid clinic at a younger
age than children with a parent with CVD (11.1 vs 12.1 years; p=0.392), but they
started statin treatment a bit older (14.2 vs 13.9 years, p=0.231), both not
 significant.
Table 2. General characteristics of FH parents and FH grandparents
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Inheritance (%)
Caucasian Etnicity, n (%)
History of CVD, n (%)
Mortality parent, n (%)
Age (yrs) 1st CVD event (mean±SD)
Untreated total cholesterol (mmol/l)
Index parent
Grandparents with FH
History of CVD grandparents
Age (yrs) 1st CVD event (mean±SD)
Parents
with FH
(n=205)
100
194 (95)
41 (20)
5 (2.4)
41±8.4
9.3±1.9
39 (82)
49 (102)
51±11.1
Paternal
(n=114)
56
111 (97)
33 (29)
5 (4.4)
42±8.6
9.4±1.7
40 (46)
Maternal
(n=91)
44
84 (92)
8 (9)
0 (0)
40±8.3
9.3±2.1
37 (34)
p-value
0.18
0.002
0.54
0.043
0.88
Oldest child per parent selected, CVD= cardiovascular disease, FH= familial hypercholesterolemia
Discussion
Even in the setting of active cascade screening, 1:5 children with FH are identi-
fied because their parent experienced CVD, mostly at a premature age. An ear-
lier study from The Netherlands revealed a higher percentage of CVD (31%) in
first-degree relatives of genetically confirmed FH children with a similar age and
lipid profile compared to our study 9. This difference might be the result of the
effect of nationwide cascade screening. Another explanation could be a referral
bias towards a more severe phenotype as the inclusion of this study took place
earlier, 1989-2001 when treating FH children was not common practice. 
Compared to other countries, our data are in line with findings from FH children
in Norway which also show 21% premature CVD in their parents with FH 10. In
this study children were identified through screening of families with a known
mutation or referred to the lipid clinic.
Although not significant, children with a parent without CVD visit the lipid clinic
at a younger age than children with parents with CVD (11.1 vs 12.1 years). This
finding highlights the result of the active screening program, bringing these
children into attention at an early age. 
Children with a parent with CVD started with a statin a few months earlier (13.9
vs 14.2 years), suggesting a more proactive treatment in these children. The
mean age of starting treatment at 13.6 years is in line with another large cohort
of FH children in The Netherlands 11. Our results show that we don’t fulfil the
current guideline for screening and starting statin treatment in FH children.
 Several studies demonstrate atherosclerosis starts already in young children with
FH 12, only since 2013 panels and guidelines, recommended that children with
suspected FH should be screened between the ages of 5 and 10 years and start
with a statin and lifestyle advices about smoking, healthy diet and physical activity
when LDL-C levels are >4.0 mmol/l between the age of 8 and 10 years 13, 14.
On the one hand one might argue that the prevalence of 1:5 parents with CVD
is high; children ≤18 years should not have a parent with premature CVD. On
the other hand a lot of progress has been achieved in the last two decades since
grandparents experienced more CVD. Although the grandparents are older, the
expectation based on current data is that the percentage CVD in the parents
will remain lower. This can mainly be explained due to the efficacy of statin treat-
ment available since 1990 but also through the systematic approach by the cas-
cade screening 3,15. Patient tailored education and annual follow up by the
physician and nurse practitioner of our CVG team working together with the
 national FH foundation, brings children with FH timely into clinical attention. 
This study has a number of limitations. Our data are from a single tertiary referral
centre. The majority of our study population is Caucasian, while 21% of Dutch
population are non-Caucasian. Therefore we cannot extrapolate our results to
other ethnicities. The strength of this study is the complete data collection in a
relatively large group of children with FH and their FH parent and FH grand -
parent. 
Cascade screening of familial hypercholesterolemia must go on
35
Conclusions and recommendations 
The fact that CVD is still a presenting event of FH in especially fathers, shows
that nationwide screening might have been terminated too early. Therefore we
recommend to proceed the cascade screening by genetic fieldworkers in The
Netherlands as well as in other countries. It ensures that the next generation
will be in clinical attention to start statin treatment in time, to prevent CVD.
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Abstract 
Background
Despite lipid-lowering therapy (LLT), some patients with familial hypercholes-
terolemia (FH) still develop cardiovascular events. Data about the quantification
and factors contributing to this residual risk are lacking.
Objective
This study assessed how many patients with FH developed a cardiovascular
event despite LLT and which factors contribute to this risk. 
Methods
We performed a time-dependent analysis in a cohort of consecutive heterozy-
gous FH patients using stable LLT to evaluate first and subsequent
 cardiovascular events. An univariate and multivariate regression analysis was
conducted to study the association between clinical characteristics and cardio-
vascular events.
Results
Of 821 FH patients (median age 47.4 (IQR 35.3-58.3) years) treated with LLT for
a median period of 9.5 (IQR 5.1-14.2) years, 102 patients (12%) developed car-
diovascular disease (CVD) in 8538 statin treated person years. Patients who de-
veloped a cardiovascular event had a median age of 52.0 (IQR 43.8-59.3) years.
These patients more often had previous cardiovascular events (32% vs 9%,
P<0.001), a family history of premature CVD (58% vs 40%, P=0.001), hypertension
(70% vs 22%, P<0.001), higher on-treatment low-density lipoprotein-cholesterol
(LDL-C) (162±54 vs 135±58 mg/dL, P<0.001), lower on-treatment high-density
lipoprotein cholesterol (HDL-C) (50±15 vs 54±15 mg/dL, P<0.001), and were
smokers (32% vs 14%, P<0.001), compared to patients without cardiovascular
events. In 31 patients (30%) a subsequent cardiovascular event occurred with a
median interval of 5.7 (IQR 2.4-9.3) years between events. They were more often
smokers (32% vs 10%, P=0.01) compared to patients with a single cardiovascular
event.
Conclusions
Despite LLT FH patients still develop cardiovascular events and especially
 subsequent events. Classical risk factors such as smoking and hypertension are
driving factors for this risk, indicating the high priority of optimizing risk factor
reduction in addition to maximum LLT.
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Introduction
Familial hypercholesterolemia (FH) is the most common inherited disorder of
the lipid metabolism, characterized by elevated levels of plasma low-density
lipoprotein-cholesterol (LDL-C). Current studies showed that the prevalence of
FH in the Caucasian population is 1:250 1. Untreated, 50% of men with FH and
33% of women with FH develop cardiovascular disease (CVD) before 45 years
and 60 years of age, respectively 2, 3. Since three decades statin treatment has
been available to lower LDL-C levels. Placebo controlled randomized trials
showed that statin therapy leads to a reduced risk of CVD 4. Although no ran-
domized CVD endpoint trials have been performed in FH patients specifically,
observational studies showed that the risk of CVD decreased substantially since
FH patients are treated with statins as lipid lowering therapy (LLT) 5, 6. Therefore
statins have been regarded first-line LLT for FH patients 7. 
Recently a new class of highly potent LLT has been developed namely Propro-
tein Convertase Subtilisin / Kexin 9 (PCSK9) inhibitors. The indication of these
drugs is restricted to patients at very high CVD risk who do not reach their LDL-C
target despite maximum tolerated LLT. FH patients who are not on target using
maximum tolerated LLT are considered to correspond to this profile and there-
fore qualify to use PCSK9 inhibitors according to consensus papers and reim-
bursement criteria 8, 9. However data, about the CVD risk among optimal treated
FH patients is lacking. Therefore, we assessed in our large cohort of FH patients
treated with LLT, how many patients still develop a cardiovascular event despite
(optimal) LLT treatment and which factors contribute to the risk of  developing
a cardiovascular event.
Methods
All FH patients treated with LLT by the Cardiovascular Genetics team at the out-
patient lipid clinic of the Erasmus MC, were potentially eligible for this study.
Inclusion criteria were: adult patients (age ≥18 years) diagnosed with hetero -
zygous FH who used LLT between 1 January 1989 and April 2016. 
The diagnosis heterozygous FH was based on either the identification of an FH
causing pathogenic mutation in the LDLR, APOB or PCSK9 gene (genetic FH)
or a Dutch Lipid Clinic Network score of ≥6 representative of probable or defi-
nite FH (clinical FH) 10. 
Cardiovascular risk management and treatment was provided in accordance
with the European guidelines on CVD prevention in clinical practice 11, 12. During
every consultation, at least once a year, side effects and adherence of LLT was
discussed and lifestyle intervention was advised when necessary. 
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Clinical data such as LLT, LDLR, APOB and or PCSK9 gene mutations, plasma
lipid levels (triglycerides, total cholesterol, LDL-C and high-density lipoprotein
cholesterol (HDL-C)), cardiovascular events, family history of CVD and general
characteristics (age, sex and date of initiation LLT) were collected from the pa-
tients’ files and entered in a dedicated database.
Maximum LLT was defined as simvastatin ≥40 mg, atorvastatin 80 mg or rosu-
vastatin 40 mg, with or without ezetimibe 10 mg. Maximum tolerated LLT was
defined as the maximum dose of statins to which patients could tolerate without
unbearable side effects in combination with or without ezetimibe. Statin intol-
erance was defined as documented unbearable side effects of at least three
statins including low dose statins on non-daily basis 13. Target levels for LDL-C
were <100 mg/dL for primary and<70 mg/dL for secondary prevention in line
with the European guidelines on CVD prevention in clinical practice 7.
Hypertension was defined as blood pressure >140/>90 mmHg on more than
two occasions or the use of a antihypertensive medication 14. Diabetes mellitus
(type 1 and 2) was diagnosed according to the American Diabetes Association
or the use of anti-diabetic medication 15. Smoking status was determined by
start and stop dates from the patients file. Quit smoking was defined as stopped
smoking >1 year.
Cardiovascular events were defined as: myocardial infarction, angina pectoris
confirmed by cardiologist, coronary artery bypass grafting or percutaneous
coronary intervention, transient ischemic accident or stroke diagnosed by a neu-
rologist or peripheral arterial disease (PAD), diagnosed by vascular surgeon 6.
Cardiovascular events were assessed by a researcher (AGM) from the patients'
medical records. Premature CVD was defined as CVD <55 years in men and <60
years in women 6. 
The time to cardiovascular events was measured from the date of starting LLT
to an event or to the end of study (31 March 2016). 
The Medical Ethics Committee of the Erasmus medical Center reviewed the
study (MEC 2016-220) and since this study was not subjected to the Dutch Med-
ical Research Involving Human Subjects Act no approval was required. The study
was conducted according to the Helsinki Declaration 16. 
Statistics 
Categorical variables are reported as numbers (percentage) and continuous
variables as mean±standard deviation (SD) or median with interquartile ranges
(IQR), as appropriate. Normal distribution was tested by the Shapiro-Wilks test.
Differences between patients with and without a cardiovascular event after start-
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ing LLT were analysed by chi-square and the Student’s t-test or Mann Whitney
as appropriate. Subsequently, we performed univariate and multivariate logistic
regression for analysing the association between clinical characteristics and car-
diovascular events during the follow-up period. The multivariate logistic regres-
sion model was constructed selecting all significant univariate risk factors and
sex. In this model, we adjusted for age, sex, smoking status, body mass index,
history of hypertension, family history of premature CVD, history of CVD before
starting LLT, HDL-C, LDL-C and triglyceride levels. Smoking status was catego-
rized in never, quit smokers >1 year, and current smokers (current smokers and
quit smoking ≤1 year). HDL-C levels were categorized into >39 mg/dL and ≤39
mg/dL, LDL-C levels into <100 mg/dL and ≥100 mg/dL and triglyceride levels
into <177 mg/dL and ≥177 mg/dL. Kaplan-Meier curves were computed to eval-
uate the risk of cardiovascular events over time by status of smoking and history
of hypertension. For all tests a p-value (2 sided) less than 0.05 was considered
statistically significant. 
All data were analysed anonymously using SPSS Statistics for Windows, Version
23.0 (IBM Corp).
Results 
We analyzed 821 FH patients (53% women) using LLT, with a median age of 47.4
(IQR 35.3-58.3) years, of whom 75% carried a LDLR or APOB mutation. Baseline
characteristics are shown in table 1 and show that more than half of the total
study population (61%) used maximum LLT therapy and 29% used maximum
tolerated LLT. Twenty-eight percent of the patients were diagnosed with hyper-
tension, whereas only 4% had diabetes mellitus (64% type 2). Twelve percent
experienced a cardiovascular event before LLT was initiated (table 1). The
 median years of statin use and duration of follow-up was 9.5 (IQR 5.1-14.2) years.
In total 102 patients (12%) developed ≥1 cardiovascular event, in 8538 statin-
treated person years (16 events per 1000 statin-treated person years), despite
LLT for median 6.7 (IQR 2.6-11.7) years. Thirty-one patients developed ≥1 car-
diovascular event during LLT. The majority (74%) of the patients had CAD. In
one third of the patients who died, the cause of death was cardiovascular, most
patients (n=6) died of cancer (table 2). 
Patients with genetic FH and clinical FH had a similar risk of developing cardio-
vascular events. Patients who developed a cardiovascular event were signifi-
cantly older compared to those who did not develop cardiovascular events
(median 52.0 (IQR 43.8-59.3) years vs. 46.9 (IQR 33.3-58.1) years, P=0.001) and
started at a later age with LLT (median 43.2 (IQR 36.2-52.2) vs. 34.8 (IQR 22.2-
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Table 1. General characteristics of FH patients according to CV event at
maximum tolerated LLT
Age* (years) median (IQR)
Women, n(%)
Caucasian ethnicity, n(%)
Cardiovascular risk factors, n(%)
• Ever smoker
• Current smokers*
• BMI mean±SD
• Hypertension
• DM type 1 and 2
• Family history premature CVD
• History of CVD before LLT
FH genetic mutation, n(%) 
• LDL receptor mutations
• Apo B mutation
FH clinical criteria
Lipid lowering therapy* n(%) 
• Rosuvastatine
• Atorvastatine
• Simvastatin
• Pravastatin
• Fluvastatin
• Ezetimibe monotherapy
Intolerant; no statin
Maximum LLT
Maximum tolerated LLT
Treated Lipid values*, mean±SD
• Total-Cholesterol (mg/dL)
• LDL-Cholesterol (mg/dL)
• HDL-Cholesterol (mg/dL)
• Triglyceride (mg/dL)
LDL-C reduction >50%, n(%)
LDL-C <135 mg/dL, n(%)
LDL-C <100 mg/dL, n(%)
Total
n=821
47.4 (35.3-58.3)
437 (53)
766 (93)
356 (43)
130 (16)
26.5±4.6 
232 (28)
36  (4)
347 (42)
95  (12)
552 (67)
65  (8)
204 (25)
300 (37)
300 (37)
170 (21)
16  (2)
6   (1)
11  (1)
29  (4)
498 (61)
240 (29)
209±62
139±58
54±15
115±62
344 (42)
501 (61)
153 (19)
CV event 
on LLT 
n=102 (12%)
52.0 (43.8-59.3)
48 (47)
93 (91)
67 (66)
33 (32)
27.9±4.1
71 (70)
13 (13)
60 (59)
33 (32)
68 (67)
10 (10)  
24 (24) 
25 (25)
39 (38)
36 (35)
2  (2)
0
0
0
67 (66)
26 (26)
232±58
162±54
50±15
142±89
30 (30)
34 (34)
9 (10)
No CV event
on LLT 
n=719 (88%)
46.9 (33.3-58.1)
389 (54)
673 (94)
289 (40)
97 (14)
26.3±4.6
161 (22)
23  (3)
287 (40)
62  (9)
484 (67)
55  (8) 
180 (25)
275 (38)
261 (36)
134 (19)
14  (2)
6   (1)
11  (1)
29  (4)
431 (60)
214 (30)
205±62
135±58
54±15
115±62
314 (44)
467 (65)
144 (21)
p
0.001
0.20
0.39
<0.001
<0.001
0.002
<0.001
<0.001
<0.001
<0.001
0.91
0.43
0.81
0.040
0.28
0.42
<0.001
<0.001
<0.001
0.001
0.009
<0.001
0.008
BMI= body mass index; CVD= cardiovascular disease; DM= diabetes mellitus; HDL= high density lipoprotein;
LDL=low density lipoprotein; LLT= lipid lowering therapy *At first event or 31-03-2016
Characteristics
47.2 years, P<0.001). Patients with CVD during LLT had more classical cardio-
vascular risk factors such as smoking (32% vs 14%, P<0.001), hypertension (70%
vs 22%, P<0.001), diabetes mellitus (13% vs 3%), a higher body mass index
(27.9±4.1 vs 26.3±4.6, P=0.002), more often a history of CVD before LLT initiation
(32% vs 9%, P<0.001) and a family history of premature CVD (59% vs 40%,
P<0.001). Moreover, treated total cholesterol, LDL-C and triglyceride levels were
higher and HDL-C was significantly lower in patients who developed a cardio-
vascular event compared to those who did not develop a cardiovascular event.
The treatment goal of LDL-C <100 mg/dL or LDL-C <135 mg/dl as well as LDL-C
reduction ≥50% was less often achieved in patients who developed a cardio-
vascular event CVD (table 1). Of the 344 patients who achieved LDL-C reduction
≥50%, 30 (9%) developed a cardiovascular event and of the 472 patients who
had an LDL-C reduction of <50%, 72 (15%) developed a cardiovascular event.
Of the 501 patients who achieved an LDL-C <135 mg/dL of these 34 (7%) de-
veloped a cardiovascular event and of the 317 patients with an LDL–C ≥135
mg/dL of these 68 (21%) developed a cardiovascular event. 
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Table 2. Cardiovascular outcomes in FH cohort during median 6.7 years of
lipid lowering therapy
All-cause mortality, n
• Cardiovascular mortality 
• Cancer
• Other
Cardiovascular events, n(%)
Coronary artery disease, n(%)
• Myocardial infarction 
• Angina pectoris
• PCI/CABG
Cerebro-vascular events, n(%)
• TIA
• Stroke
Peripheral vessel disease, n(%)
• PAD 
Total Cohort
n=821
12 
4
6
2
102 (12)
75 (74)
36 (35)
12 (12)
27 (27)
23 (23)
13 (13)
10 (10)
4 (4)
4 (4)
CVD= cardiovascular disease; PCI= percutaneous coronary intervention;
CABG= coronary artery bypass grafting; TIA= transient ischemic accident; 
PAD= peripheral arterial disease
Cardiovascular outcomes
Of all variables 11 significant determinants were identified for the multivariate
model (table 3). Seven determinants were independently associated with the
occurrence of cardiovascular events. In addition to age, current smoking, history
of hypertension, family history of CVD, history of CVD before starting LLT,
treated lipid levels; high LDL-C and low HDL-C remained in the model. The
analysis including age at initiation of LLT showed identical results. Current smok-
ers (n=130, 16%) had a 4 times (OR 4.24; 95% CI 2.14-8.37) increased risk of de-
veloping a cardiovascular event and therefore a lower CVD-free survival
compared to patients who never smoked, or those who quit smoking (table 3,
figure 1). Furthermore, patients with hypertension had an almost 3 times higher
risk of developing cardiovascular events (OR 2.95; 95% CI 1.68-5.18) and conse-
quently a lower CVD-free survival (table 3, figure 2). Other factors associated
with an cardiovascular event were CVD prior to the start of LLT (OR 2.47; 95%
CI 1.34-4.57), a family history of premature CVD (OR 1.85; 95% CI 1.10-3.11),
higher LDL-C levels (OR 3.64; 95% CI 1.60-8.29) and lower HDL-C levels (OR
4.27; 95% CI 2.18-8.36).
Thirty percent (n=31) of the treated patients with a first cardiovascular event ex-
perienced a subsequent event after a median of 5.7 (IQR 2.4-9.3) years at a me-
dian age of 58.6 (IQR 48.7-65.6) years with a median treatment duration of 12.3
(IQR 9.0-16.8) years. Patients, who developed a subsequent cardiovascular
event, were more often current smokers (32% vs 10%, P=0.01) and showed a
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Figure 1. CVD free survival of FH patients and smoking status
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Table 3. Associations between determinants and cardiovascular events
Age (years) 
Sex
Cardiovascular risk factors
Never smokers
Current smokers
Quit smokers >1 year
DM type 1 and 2
BMI 
Hypertension 
Family history premature CVD
History of CVD before LLT
Treated lipid levels
Triglyceride >177 mg/dL
HDL-cholesterol <39 mg/dL
LDL-cholesterol >100 mg/dL
Univariate
(OR, 95%CI)
1.07 (1.05-1.08)
0.75 (0.50-1.14)
1
4.18 (2.48-7.06)
2.18 (1.32-3.59)
4.39 (2.15-8.97)
1.07 (1.03-1.12)
7.94 (5.03-12.54)
2.15 (1.41-3.28)
5.07 (3.11-8.27)
1.95 (1.13-3.36)
3.80 (2.36-6.13)
2.47 (1.21-5.03)
P
<0.001
0.18
<0.001
0.002
<0.001
0.001
<0.001
<0.001
<0.001
0.016
<0.001
0.013
Adjusted*
(OR, 95%CI)
1.07 (1.04-1.10)
1.07 (0.62-1.84)
1
4.24 (2.14-8.37)
1.21 (0.66-2.20)
2.32 (0.98-5.52)
1.01 (0.96-1.07)
2.95 (1.68-5.18)
1.85 (1.10-3.11)
2.47 (1.34-4.57)
0.71 (0.36-1.43)
4.27 (2.18-8.36)
3.64 (1.60-8.29)
p
<0.001
0.82
<0.001
0.54
0.06
0.71
<0.001
0.021
0.004
0.34
<0.001
0.002
BMI= body mass index; CVD= cardiovascular disease; DM= diabetes mellitus; LLT= lipid lowering therapy;
LDL=low density lipoprotein; HDL= high density lipoprotein
*Adjusted for: age, sex, smoking, DM, BMI, history of hypertension, family history of CVD, history of CVD
 before starting LLT, triglyceride, high LDL-C, low HDL-C.
Figure 2. CVD free survival of FH patients and hypertension
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Characteristics
trend towards more often having (history) hypertension (84% vs 63%, P=0.06),
compared to those who remained without a subsequent cardiovascular event.
However LDL-C  levels were similar among these groups (P=0.54) (table 4).
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Table 4. Characteristics of FH patients using lipid-lowering therapy who did
and who did not develop a second cardiovascular event
Age* (years) median (IQR)
Women, n(%)
Caucasian ethnicity, n(%)
Cardiovascular risk factors, n(%)
• Current smokers*
• BMI, mean±SD
• Hypertension
• DM
• Family history premature CVD
• History of CVD before LLT
FH genetic mutation, n(%)
• LDL receptor mutations 
• Apo B mutation
FH clinical criteria
Lipid lowering therapy* n(%)
• Rosuvastatine
• Atorvastatine
• Simvastatin
• Pravastatin
• Fluvastatin
• Ezetimibe monotherapy
Intolerant; no statin
Maximum therapy, n(%)
Maximum tolerated therapy, n(%)
Treated lipid levels*, mean±SD
LDL-cholesterol (mg/dL) mean±SD
LDL-C <70 mg/dL, n(%)
LDL-C <100 mg/dL, n(%)
Second
event
on LLT
n=31 
58.6 (48.7-65.6)
13 (42)
26 (84)
10 (32)
27.4±4.3
26 (84)
4  (13)
19 (61)
12 (39)
20 (65)
4  (13)
7  (23)
5  (16)
17 (55)
7  (23)
1  (3)
0 
0
1  (3)
19 (61)
9  (29)
147±62
1  (3)
6  (20)
No second
event 
on LLT
n=71
57.1 (48.4-66.6)
35 (49)
67 (94)
7 (10)
28.1±4.0
45 (63)
9  (13)
41 (58)
21 (30)
48 (67)
6  (9)
17 (24)
41 (58)
17 (24)
8  (11)
0  (0)
1
1
4  (6)
49 (69)
18 (25)
139±62
6  (9)
17 (24)
p
0.82
0.53
0.13
0.011
0.44
0.060
1.0
0.83
0.37
0.82
0.49
1.00
<0.001
0.003
0.22
n.a.
n.a.
n.a.
n.a.
0.50
0.81
0.54
0.67
0.80
LDL= low density lipoprotein; CVD= cardiovascular disease; BMI= body mass index; DM= diabetes
mellitus; LLT= lipid lowering therapy * At second event or 31-03-2016
Characteristics
Discussion
Our results show that despite maximum (tolerated) LLT, 12% of our FH patients
developed a cardiovascular event. Modifiable factors associated with this resi -
dual CVD risk were smoking and hypertension as well as LDL-C levels and HDL-C
levels. Among patients who developed an event despite LLT, 30% developed a
subsequent cardiovascular event, which was also associated with smoking. 
Although observational studies showed that LLT reduces CVD in FH patients,
data on the quantification of the residual risk of CVD in LLT-treated FH patients
is sparse. Cross-sectional studies in FH patients using LLT reported the preva-
lence of CVD between 9-22% 17-19. Only one study, a Spanish cross-sectional
cohort, reports about second cardiovascular events among FH patients. In this
study the proportion of women who developed a subsequent cardiovascular
event was similar to our study (27% vs. 28% respectively). However, in the
 Spanish cohort much more men developed a subsequent event compared to
our study (60% vs 33%, respectively) 19. In all aforementioned cross-sectional
studies no information was provided whether these cardiovascular events
 occurred before the initiation of LLT or during LLT. 
Previously two Dutch studies reported the cumulative event-free survival compar-
ing FH patients using statins versus no statin treatment. These studies showed a
residual risk of CVD of 11 per 1000 patient years on low-dose statin therapy and
8.8 per 1000 person-years using moderate-to-high-statin therapy 5, 18. The study
of Versmissen et al., performed a model in which statin-treatment was used as
a time-dependent variable, mimicking a randomized clinical trial 5. Besseling,
et al. coupled data from the Dutch national FH screening program to the
Pharmo RLS databases which included the national registry on mortality and
hospitalization as well as in-and out-patient pharmacies to assess the residual
risk of CVD in FH patients. No individual hospital records were available and
risk factors were self-reported. In the final analysis only 2.46% of the total FH
population could be analysed by this linkage and patients included in the final
analysis had a more unfavourable risk profile compared to patients who were
not included 20. Therefore a selection bias cannot be excluded. Our study differs
from the aforementioned studies because our aim was not to compare CVD risk
of FH patients with and without LLT, but to focus upon the variation of CVD
among FH patients using long-term LLT as the benefit of LLT in this population
is considered evident. 
Both genetic and lifestyle factors contribute to the risk of CVD 21, 22. Similar to
the general population not only LDL-C but also other risk factors such as smok-
ing, hypertension, diabetes mellitus, elevated lipoprotein(a) and low HDL-C le -
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vels have been associated with CVD in FH patients. Previously Jansen et al.
showed in a large FH cohort study that classical risk factors such as smoking
and hypertension were independent predictors for developing CVD 23. In con-
trast to the current study it was not recorded when and if LLT was initiated. Also,
in our FH study population, classical non-lipid risk factors such as hypertension
and especially smoking, were independent risk factors for developing cardio-
vascular events. An important observation is the beneficial effect of those who
stopped smoking, had a lower risk of CVD. This risk was almost comparable to
never smokers. In our population of treated FH patients, 18/33; 55% stopped
smoking after a cardiovascular event. Although this seems disappointing, the
result is in line with the EUROASPIRE study in which 51% ceased to smoke after
a cardiovascular event 24. Sadly thus far, the success of stop smoking programs
in adults is limited 25. Therefore, in our opinion for optimal CVD prevention, in-
tensified lifestyle intervention with a focus on smoking cessation irrespective of
a cardiovascular event remains crucial 26. Collaboration with professional part-
ners de dicated to stop-smoking and lifestyle intervention can improve cardio-
vascular risk management 27.
In addition to classical risk factors, LDL-C levels not on target, and low HDL-C
levels were also associated with cardiovascular events in those patients who de-
veloped a first cardiovascular event during LLT. Previous studies showed that
only a small percentage of FH patients reached target LDL-C levels. In the cohort
of Pijlman et al., only 21% of the FH patients reached LDL-C target levels 17.
Among the factors affecting the low level of LDL-C goal attainment are  patient-
related factors such as statin side effects and insufficient adherence on the one
hand, and on the other, laxity of healthcare professionals to start or adequately
up-titrate LLT. Lastly, in patients with very high untreated LDL-C levels, maximum
LLT consisting of high dose statin in combination with ezetimibe is often not
sufficient to reach LDL-C targets 17. In our population the majority of patients
used either maximum LLT (61%) or maximum tolerated LLT (29%) and in a subset
of these patients we previously showed that the adherence of our patients was
as high as 89% 28. However, still only 19% of our patients reached an LDL-C level
of <100 mg/dL. 
Increased levels of lipoprotein(a) [Lp(a)] are an independent risk factor of CVD 29.
Patients with FH have higher Lp(a) levels compared to non-FH subjects. Current
lipid-lowering therapy such as statins and ezetimibe do not reduce Lp(a). There-
fore it is not unexpected that increased Lp(a) concentrations have been associ-
ated with residual CVD risk both in FH and non-FH patients 30. A problem with
Lp(a) measurement is the standardization of the used immune-assays. During
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follow-up several different assays have been used in our out-patient clinic which
are not comparable and were mostly not isoform independent. Therefore it was
not possible to assess the effect of Lp(a) on the residual risk in our study. 
The new class of lipid-lowering medication, PCSK9 inhibitors lower LDL-C on
average 54% compared to placebo, in addition to LLT 31. Recently, the Further
Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With
 Elevated Risk (FOURIER) trial showed an additional 59% reduction in LDL-C and
a reduction of 15% in composite CVD outcome in patients using evolocumab
compared to placebo 32. Randomized controlled trials in FH patients showed a
43-66% reduction in LDL-C levels 33, 34. Reimbursement criteria differ interna-
tionally, but in general the costly PCSK9 inhibitors are reserved to patients who
have the highest risk of CVD despite current LLT 35.
The current study reveals a clear contribution of classical risk factors which are
partly modifiable in a consecutive cohort of present-day FH patients using LLT
with detailed follow-up data. Therefore, in our viewpoint, clinicians should not
solely focus on lipid parameters such as LDL-C but also pay attention to classical
risk factors such as smoking and hypertension. Initiation of PCSK9 inhibitors will
not become the solution to eradicate CVD risk in this population as long as
other risk factors are not treated. Consequently, we propose a multifactorial ap-
proach for treatment of FH patients evidently optimizing maximal LLT, but with-
out disregarding to concentrate on non-lipid risk factors. 
Our study has several strengths and limitations. This is the first study with statin-
years in a systematically well-phenotyped cohort of FH patients using long-term
LLT to determine the contribution of additional risk factors of CVD identifying
individuals at high risk. Because our study included a follow-up duration of many
years we had to take several cardiovascular disease prevention guidelines into
account. Until 2007 the European CVD prevention guideline with an LDL-C treat-
ment goal in primary prevention was ≤3.5 mmol/l, subsequently an LDL-C of
≤2.5 mmol/l was advised. Moreover, we present a single-centre cohort in a spe-
cialized tertiary hospital, therefore external validation is not ensured. Finally,
lipoprotein(a) levels, a lipid factor often associated with residual cardiovascular
risk, was not available for a large number of patients and could therefore not
be evaluated.
Conclusions and recommendations
Despite long-term optimal LLT, 12% of our FH patients developed a cardiovas-
cular event. In addition to lipid parameters, classical risk factors, especially
smoking and hypertension, contributed to the cardiovascular events. Moreover,
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almost one third of statin-treated FH patients with a cardiovascular event de-
veloped a subsequent event associated with smoking and hypertension, under-
lining the need for improved CVD prevention. Treatment of FH patients should,
therefore, not only focus on optimizing LDL-C levels, but also on improving
other CVD risk factors.
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Abstract 
Purpose
Familial hypercholesterolemia (FH) is an autosomal dominant disorder, associ-
ated with a high risk of premature coronary heart disease (CHD). CHD preven-
tion consists of lifestyle changes combined with lifelong statin treatment. Good
adherence to statins reduces the risk of events substantially. This study was
 designed to identify determinants of non-adherence and to develop a model
predicting non-adherence. 
Methods
A single centre survey including all consecutive heterozygous FH patients above
age 18 years, who were treated by a specialized team in the outpatient clinic of
a university hospital in The Netherlands between 2008 and 2009. In addition to
clinical data, patients completed a questionnaire concerning medication adher-
ence. 
Results
We analyzed 321 patients (169 women) with a statin prescription, whose mean
age was 46±14 years (± SD) and 13% of the patients had CHD. The untreated
mean total cholesterol was 10±2.3 mmol/l. On average patients were 10 years
on cholesterol-lowering therapy (range 1-29 years). Adherence was reported by
89% of the patients (>90% adherence). Non-adherence was associated with
younger age (OR=10.64, 95% CI 2.86-39.68), high total cholesterol level during
prescription (OR=4.29, 95% CI 1.86-9.89) and a relatively low untreated total
cholesterol level (OR= 3.94 95% CI 1.39-11.14). A prediction model based on
these three determinants had a c-index of 0.78 and a calibration with P=0.88.
Conclusion
Based on three independent determinants, a prediction model is developed to
identify non-adherent FH patients. This model needs to be tested in future
prospective research. It might be a first step in improving statin adherence in
this extremely high risk group.
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Introduction
Familial hypercholesterolemia is associated with a severe risk of coronary heart
disease 1, 2. Effective CHD prevention is available consisting of lifestyle changes
and lifelong statin treatment 3-6. Remarkably, the efficacy of statin treatment of
FH patients was much larger than observed in most large primary prevention
trials; 76% versus approximately 37% CHD risk reduction, respectively 7-9. 
Non-adherence with prescribed drug regimens is a pervasive medical problem.
Adherence rates are low in patients with chronic diseases 10. Obviously, non-ad-
herence is a threat to effective cardiovascular prevention in FH patients. Statin
treatment can be considered as therapy in the causal pathway of FH, therefore
good adherence is a necessity. In primary prevention studies in patients with
hypertension and diabetes, only half of the patients took at least 80% of the
prescribed statin dosage after one year of follow-up. Clearly, the retention in
treatment decreases over time 11. Adherence is defined as 'the extent to which
patients follow the recommendations by their healthcare professional' 12. In the
present study, we specifically focus on the treatment with statins.
A large number of predictors of poor adherence to different medications have
been described that may also apply to statins: primary prevention, low level of
education, low socioeconomic status, psychological problems particularly
 depression, side effects, patient’s lack of belief in benefit, complexity of therapy
especially the start of co-medications, age and a low rate of control appoint-
ments 4, 13-17. Although several studies described the aforementioned predictors
of non-adherence, it is not known whether these predictors have a similar impact
in the FH population. The majority of FH patients in The Netherlands are iden-
tified through family screening in order to start treatment early in adulthood.
Therefore, our patients are relatively young and mostly asymptomatic. On the
one hand one might argue that offering lifelong treatment to asymptomatic
persons is unlikely to obtain high adherence. On the other hand a lot attention
has been paid to the high morbidity scores linked to reduced adherence in par-
ticular of statins 18, 19. 
There is potentially much to be gained by improving adherence. A number of
possibilities could be considered. Motivational interviewing 20, 21, the Medication
Electronic Monitoring System (MEMS) and strategies for enhancing self-efficacy
are options 22-25. However non-adherence has to be recognized first. Healthcare
professionals do not have many opportunities to identify non-adherence with
confidence. The goal of our study was to develop a prediction model for iden-
tification of FH patients who do not adhere with statin use. 
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Patients and methods
Participants
Our tertiary referral centre treats patients with cardiovascular diseases and dif-
ferent types of inherited lipid disorders. The majority of patients (70%) referred
between 1 January 2008 and 31 December 2009, were diagnosed with FH. All
consecutive adult patients with heterozygous FH were considered eligible for
inclusion in this study. The diagnosis FH was based on either the identification
of an FH causing mutation (in the LDL-receptor or Apo B gene) or on the fol-
lowing clinical criteria: LDL cholesterol level >the 95th for age and gender spe-
cific percentile in combination with at least one the following; presence of
xanthomas, LDL cholesterol >95th percentile for age and sex in a first degree
relative or premature CHD in a first degree relative (defined as male <55y,
 female <60y). The criteria of Aalst–Cohen were used 26. 
The medical ethical committee of our institute approved the protocol and all
participants gave written informed consent.
Study design
All patients were carefully monitored annually at the lipid clinic by a specialized
vascular nurse, according to the European guideline for the management of
dyslipidaemias 3. Side effects were discussed and statins were changed when
necessary. Clinical data was collected from the patients’ files. 
The development of the questionnaire occurred in cooperation with experts
from the Cardio Vascular Genetic (CVG) team. Patients were asked how often
they deviated from the medication regime. They could choose one of the
 following options; option 1 was never, 1-2 times in a year; option 2 was rarely, 
1-4 times in a quartile; option 3 was regularly, 1-2 times in two weeks; and option
4 was often, 3 or more times in one week. We defined adherence as the use of
the prescribed medication for more than 90% of the time (option 1 and 2) and
non-adherence as less than 90% (option 3 and 4). 
The questions focusing on not taking statins originate from the Medication
 Adherence Report Scale (MARS) which has a good reliability 27. 
Hypertension and diabetes mellitus were mentioned as relevant co-morbidities.
Hypertension was defined as blood pressure >140/>90 mmHg on more than 
2 occasions or the use of a prescribed antihypertensive medication and type 2
diabetes mellitus was diagnosed according to WHO criteria or the use of pre-
scribed anti-diabetic medication 28. 
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Statistical analysis
All data were analysed anonymously by SPSS (version 17.0). Chi-square tests to
assess differences in proportions, and the student t-test to assess differences
in means were used. The values are presented as mean±Standard Deviation
(S.D.), unless otherwise specified. Dichotomous variables are presented as num-
bers and percentages. Statistical significance was defined as P ≤0.05. 
For the prediction model, to estimate non-adherence, univariate and multivari-
ate analysis were used for variable selection. Univariate logistic regression analy-
sis was applied to study the relation between potential predictors for
non-adherence. In addition to age and gender the 4 most significant variables
in the univariate analysis, based on Wald χ2 test, were included in the multivari-
ate analysis. Only 4 additional variables were added with respect to the limited
numbers of patients 29.
The multivariate logistic regression model was constructed using backward
elimination of the least significant variables until all variables in the model had
a p-value ≤0.15. We accepted a type I error of 15% for all variables. Subse-
quently, a risk score to predict non-adherence (adherence <90%) was devel-
oped, which included all relevant risk factors, which were weighted according
to the natural logarithm (Ln) of the corresponding odds ratio (OR). Age,
 untreated and treated total cholesterol were categorized in: age 18 to 35, 36 to
50, and ≥51 years; untreated total cholesterol <8 mmol/l, 8 to 10 mmol/l and
>10 mmol/l; treated total cholesterol <5 mmol/l and ≥5 mmol/l.
The performance of the final model was studied with respect to discrimination,
as indicated by the C-index and calibration, as shown with the Hosmer-
Lemeshow goodness-of-fit test for predicted versus observed probabilities. 
Results 
A total of 321 out of 407 consecutive FH patients were included in the present
study. A minority of the outpatient clinic population was not included in the
study; n=26 did not gave informed consent, n=16 returned the questionnaire
after the deadline and n=44 did not fulfil the inclusion criteria. Of those patients
30 had an age below 18 years, 3 were pregnant, 3 had a normal cholesterol (LDL
cholesterol <3 mmol/l), 1 patient just recently started statin treatment and 7
 patients were without statins because of severe side effects on prior prescrip-
tions. The baseline characteristics of the FH population and their adherence are
shown in table 1. The response rate of the questionnaire was 90%. Statins
 reduced the untreated total cholesterol level with 45.5 %. Of the patients with
a treated LDL-C ≥2.5 mmol/l (n=108), either the treating physician was satisfied
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with an LDL-C under 2.8 mmol/l (n=14), or patients could not tolerate a higher
dose or stronger statin (n=35) or the statin therapy was in the up-titration phase
(n=59). The treatment goal for LDL-C <2.5 mmol/l was only achieved in 18.7%
of the patients. Nearly 40% of the patient’s LDL-C was above 3.5 mmol/l. Max-
imum therapy was prescribed in more than half of the patients (58.3%, n=187).
Patients on maximum therapy achieved the treatment goal in 18.2%. 
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Table 1. Characteristics of patients according to adherence
Age (years)
Women
Cardiovascular risk factors
Smokers (current)
Hypertension
Diabetes
History of CVD
Family history premature CHD
FH diagnosis
LDL receptor gene mutation
Apo B gene mutation
Clinical grounds
Side effects never 
Side effects current statin
Body Mass Index (kg/m2)
Statin use (years)
Untreated total cholesterol
Treated lipid values
Total cholesterol
LDL cholesterol (mmol/l)
HDL cholesterol (mmol/l)
Triglyceride (mmol/l)
LDL= low density lipoprotein
HDL= high density lipoprotein
CHD= coronary heart disease
CVD= cardiovascular disease
% n=321
45.6±13.9
52.6 (169)
15.6 (50)
15.6 (50)
3.1 (10)
12.8 (41)
46.1 (148)
72.4 (232)
5.5 (18)
22.1 (71)
45.8 (147)
27.4 (88)
26.1±4.4
9.8±6.9
10.0±2.3
5.2±1.3
3.4±1.1
1.3±0.4
1.17±0.6
Adherent
(>90%)
89% n=285
47±13.8
53 (151)
14 (41)
17 (48)
4 (10)
14 (40)
50 (142)
46 (132)
28 (81)
26±4.3
10.2±7.0
10.1±2.3
5.2±1.2
3.3±1.0
1.3±0.4
1.1±0.6
Non Adherent
(<90%)
11% n=36
38±12.1
50 (18)
25 (9)
11 (4)
0 (0)
3 (1) 
42 (15)
42 (15)
19 (7) 
26±5.1
6.4±4.4 
9.0±2.1
6.0±1.8
4.1±1.6
1.2±0.3
1.3±0.6
p
<0.01
0.7
0.1
0.8
0.9
0.09
0.4
0.60
0.3
0.9
0.01
0.01
<0.01
<0.01
0.09
0.07
LDL low density lipoprotein, HDL high density lipoprotein, CHD coronary heart disease, 
CVD cardiovascular disease.
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Non-adherence, using less than 90% of the prescribed medication, was reported
by 11% of the patients. They were significantly younger than adherent patients
(38±12.1 vs. 47±14.0 years; p<0.001) and shorter on statin prescription (6.4±4.4
vs. 10.2±7.0 years; p=0.005). As expected, they had on average higher LDL-C
levels than adherent patients (4.1±1.6 vs. 3.3±1.0 mmol/l; p<0.001). Their treated
total cholesterol was almost 1 mmol/l higher (6.0±1.8 vs. 5.2±1.2 p=0.001), de-
spite lower untreated total cholesterol levels (9.0±2.1 vs. 10.1±2.3).
Potentially relevant determinants of non-adherence were tested in a univariate
analysis model for non-adherence in individual FH patients (table 1). All reasons
mentioned by the patients for being non-adherent, were having side effects,
being not at home, lack of drugs, aversion of medication or no time to take
medication. These answers were non-significant in de univariate analysis (data
not shown). 
A total of 6 determinants were selected for a multivariate model (table 2). Three
independent determinants for non-adherence were identified: age, untreated
total cholesterol and treated total cholesterol remained in the model. Patients
younger than 36 years (n=77, 24%) were almost 10 times (OR 10.64; 95% CI 2.86-
39.68) more non-adherent than patients older than 51 years (n=121, 38%). Pa-
Table 2. Associations between determinants and non-adherence
Women
Age (years)
18 – 35
36 – 50 
≥51 
Statin use (years)
Untreated total cholesterol
<8 mmol/l
8-10 mmol/l
>10 mmol/l
Treated total cholesterol
≥5 mmol/l
<5 mmol/l
LDL cholesterol (mmol/l)
Crude OR
(95%CI) 
0.89 (0.44-1.76)
0.95 (0.93-0.98)
7.80 (2.50-24.36)
4.53 (1.47-13.99)
1
0.90 (0.84-0.97)
3.57 (1.43-8.88)
1.45 (0.63-3.32)
1
1.47 (1.17-1.84)
1
1.63 (1.26-2.10)
Adjusted OR
(95%CI)
10.64 (2.86-39.68)
7.06 (1.95-25.48)
1
3.94 (1.39-11.14)
1.69 (0.68-4.16)
1
4.29 (1.86-9.89)
1
p
<0.01
<0.01
<0.01
0.01
0.3
0.04
<0.01
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Table 3. Non-adherence risk score
Characteristics
Untreated cholesterol <8 mmol/l
Untreated cholesterol 8-10 mmol/l
Untreated cholesterol >10 mmol/l
Age 18 -35 years
Age 36 -50 years
Age ≥51 years
Treated total cholesterol
≥5 mmol/l
<5 mmol/l
Add the points to obtain the risk score
Multivariate
Ln OR (95% CI)
1.37
0.52
-
2.37
1.95
-
1.46
-
Contribution to
the non-
adherence 
risk score
Points
3
1
0
5
4
0
3
0 +
0-11
tients with an untreated baseline cholesterol below 8 mmol/l were 4 times more
(OR 3.94; 95% CI 1.39-11.14) non-adherent than patients with an untreated cho-
lesterol above 10 mmol/l. Patients with a treated cholesterol above 5 mmol/l
were 4 times (OR 4.29; 95% CI 1.86-9.89) more frequent non-adherent as well.
The non-adherence risk score was based on the natural logarithm of the OR’s
of the variables in the final multivariable model, presented in table 3. The 
c-index for the multivariable non-adherent model was 0.78. The Hosmer-
Lemeshow goodness-of-fit test was not significant (P = 0.88). Adding all appro-
priate points from the variables results in a non-adherence risk score (0-11 points)
with an increasing chance of non-adherence with a higher score. In figure 1, the
risk score for non-adherence is shown. 
Discussion
Our results demonstrate that statins reduced the untreated total cholesterol
level with 45.5% in our heterozygous FH study population. In only 19% of
 patients the treatment goal was achieved. We assessed whether these results
were influenced by the factor non-adherence. Non-adherence of statins was re-
ported in 11% of the patients. They were younger and shorter on statin pre-
scription. They showed higher treated LDL-C and total cholesterol levels and
had lower untreated baseline cholesterol. Based on these independent vari-
ables, a non-adherence risk score calculator was developed.
The treated lipid values of our cohort are in line with a large cross-sectional
study in The Netherlands, which also revealed a significant reduction of choles-
terol levels in patients with FH 30. In the present study, the FH population is ex-
pected to have a higher increased risk for CVD, based on the higher percentage
of patients with a genetic diagnosis of FH compared to the aforementioned
study (78% versus 54%, respectively). Only a small percentage of patients (19%)
reached the treatment goal of LDL-C <2.5 mmol/l for primary cardiovascular
prevention, despite maximum statin therapy in almost 60%. More importantly,
13% of these patients, with a mean age of 46 years, had a history of a cardio-
vascular event. The low percentage of patients on target can mainly be ex-
plained by insufficient availability of strong enough cholesterol-lowering drugs
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Figure 1. Non-adherence risk score
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for FH patients. Yet, non-adherence should not be underestimated as factor for
decreasing the effectivity of statins. Data from a review of Bates et al. showed a
high frequency of statin non-adherence in several primary prevention studies
31. High adherence should be achieved since the incidence of nonfatal CAD
events can decrease substantially, if 90% of the prescribed statin is used for at
least one year 11, 32, 33. Although the monitoring of lipid lowering treatment is
recommended by several clinical guidelines, the competence to recognize non-
adherence by physicians appears poor 10, 34. In addition, knowledge of causes
of non-adherence is essential for managing patients on any medication 31. In
order to be able to identify patients at risk for non-adherence, a prediction
model was developed.
This prediction model can be used in clinical practice during patient consulta-
tion to assess and improve adherence. The variables in the model are available
in daily practice. If patients are at risk for non-adherence according to the
model, it should be discussed and guidance and support can be provided by
healthcare prescribers. For example, a 24-year-old man with an untreated total
cholesterol of 7.5 mmol/l and a treated total cholesterol of 5.5 mmol/l has a
non-adherence risk score of 11 points, indicating a non-adherence risk of 50%
(figure 1). These predictors of non-adherence are in accordance with other stu -
dies, who also reported that age and the absence of physical symptoms were
predictors of non-adherence, suggesting that these patients do not realize the
need for therapy 31. By using this prediction model time consuming interven-
tions like motivational interviewing can be limited to those who are at high risk
of being non-adherent.
In the current study, non-adherence was reported in only 11% of the study po -
pulation. This is much lower than in previous meta-analysis on statin non-adhe -
rence. Naderi et al. reported an adherence percentage of approximately 57% in
4 primary prevention studies with statins 14. Lemstra et al. described similar re-
sults in 24 cohort studies. However, a much higher percentage of adherence was
observed in the 3 RCTs. They reported percentages of adherence of 90% 17.
These differences can be explained by more frequent follow-up visits with more
lipid testing, observations and more intensive follow-up of non-adherence. Our
follow-up consists of 1 or 2 visits yearly, resulting in a similar good adherence
as in these latter more intensive studies. Hollman et al., did not show a signifi-
cant correlation between adherence and knowledge about the disease. This
might be different in our population, because we explain FH to the individual
patient, the families and colleges for patients. Moreover, they receive an expla-
nation about the effect of treatment on their lipid profile during each consulta-
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tion to increase awareness 35. Motivation and behavioral changes starts with
awareness of risk behavior, disease knowledge alone is probably insufficient to
achieve changes 36. The good adherence in our study may be based on the sys-
tematic feedback of treatment results.
It should be noted that the percentage side effects (27%) in our study is much
higher than the incidence of adverse effects of statins in RCT’s 37. They reported
a prevalence of 1-5%, while observational studies demonstrate side effects in
10%. This shows that side effect are rarely a reason for being non-adherent in
our motivated population. 
Our study has a number of strengths and limitations. The developed model
based on age, untreated and treated total cholesterol is easily to use during
patient consultation. It should, however, be noted that self-reported question-
naires are known to collect social desirable answers and overestimate adherence
compared to objectively measured adherence with for instance the Medication
Electronic Monitoring System (MEMS) 38, 39. However, our patients, who reported
non-adherence, clearly had higher LDL-C levels. Our model is developed in a
single centre FH population with a limited number of patients, and it therefore
needs validation in a larger population. Another potential limitation is that pos-
sible confounding by the care provider cannot be excluded in an open obser-
vational designed study.
In conclusion, a prediction model is developed with good discriminative capa-
bilities to identify non-adherent FH patients. Only a low percentage of non-ad-
herence was reported in our population, despite frequent side effects. Our
model might aid in improving statin adherence in this extremely high risk group,
which could potentially further prevent cardiovascular disease. This prediction
model in combination with appropriate actions needs to be tested in future
prospective research.
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Abstract 
Background
Evidence regarding management of women with familial hypercholesterolemia
(FH) remains limited. 
Objective
We examined lipid profile, lipid-lowering therapy, side effects of statins, treat-
ment effectiveness and its associated factors in women with FH and compared
the parameters with those from men.
Methods
Study population includes adult patients with FH (n=363) treated at our lipid
clinic between 2008-2010. Multivariable linear regression analysis was applied
to determine the variables associated with effectiveness of lipid-lowering treat-
ment, defined as a continuous outcome of percentage reduction in total cho-
lesterol (TC) levels in response to treatment.
Results
Women had higher TC levels at baseline compared to men (10.3±2.7 mmol/L
vs. 9.7±1.9 mmol/L P=0.02). 64.5% of women, compared to 75.7% of men,
 received maximum statin therapy (P=0.02). Nevertheless, mean percentage
 reduction in TC level was 43.9%±15.4% in women and 46.7%±14.0% in men
(P=0.08). In multivariable-adjusted models, reduction in TC levels among
women was associated positively with age (Beta; 95% confidence interval:
0.2;0.1,0.4), treatment with atorvastatin (6.6;1.6,11.7) and rosuvastatin
(6.4;0.4,12.3), maximum statin therapy (6.6;2.0,11.2); and inversely with presence
of side effects (-5.4;-9.9,-0.9). Among men, it showed a positive association with
lipid-lowering diet (8.3; 1.8,14.7), addition of ezetimibe to atorvastatin
(6.9;2.8,11.1) and to rosuvastatin (9.1;2.7,15.5); and inverse associations with
smoking (-5.9;-10.9,-0.9) and alcohol (-6.6;-11.2,-2.0). 
Conclusions
Our findings underscore the lower likelihood for women to receive maximum
therapy, despite their poorer lipid profile, and emphasize the impact of statin
side effects on achieving the desirable clinical outcomes among women. 
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Introduction
Familial hypercholesterolemia (FH) is the most common genetic disorder leading
to severely elevated serum cholesterol levels 1. Genetic defects in FH arise from
mutations affecting the low-density lipoprotein receptor (LDLR), Apolipoprotein
B (APOB), proprotein convertase subtilisin kexin type 9 (PCSK9) or, in rare cases,
the autosomal recessive hypercholesterolaemia (ARH) adaptor protein 2.
FH is associated with an increased risk of premature atherosclerosis. The risk of
coronary artery disease (CAD) in FH patients has been estimated as >30% in
women by age 60 and >50% in men by 50 years of age 3. Intensive lipid manage-
ment is therefore necessary to prevent cardiovascular disease (CVD) 3-6. Statins
constitute the first line treatment for patients with FH 7. Despite impro vements in
lipid-lowering therapy in the last few years, most FH patients do not achieve op-
timal therapeutic lipid levels and residual risk of CVD is still present 8, 9. 
Women with FH comprise a high-risk group which remains under-investigated
10. In other high-risk populations, such as diabetics, women seem to receive less
lipid-lowering therapy and have experienced poorer lipid control compared
men 11, 12. While higher incidence of statin adverse effects in women have been
suggested, evidence regarding gender-related statin adverse effects  remains
controversial 13-17. Based on longitudinal studies, little is known about manage-
ment of FH women compared to their male counterparts 18, 19. It is therefore es-
sential to investigate potential gender differences in management of FH
patients and the factors contributing to the effectiveness of treatment
 interventions among women and men. 
In a well-defined cohort of FH patients, we aimed to study the differences be-
tween women and men in lipid profile, lipid lowering therapy, and side effects
of statins. Further, we assessed the factors associated with treatment effective-
ness among women and men with FH.
Methods 
Study population and design
Our specialized university centre lipid clinic treats patients with cardiovascular
diseases and inherited lipid disorders, mainly FH. All consecutive adult patients
with heterozygous FH who visited our out-patient clinic between 1 January 2008
and 31 December 2009 were considered eligible for inclusion in this study.
 Diagnosis of FH was based on either identification of a FH causing mutation in
the LDLR, APOB or PCSK9 gene or on the following clinical criteria: LDL cho-
lesterol level >the 95th for age and gender specific percentile in combination
with at least one of the followings: presence of xanthomas, LDL-cholesterol level
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>95th percentile for age and sex in a first degree relative, or premature coronary
heart disease (CHD) (defined as male <55y, female <60y) in a first degree relative
using the criteria of Aalst-Cohen 20. All consecutive adult patients with heterozy-
gous FH were considered eligible for inclusion in this study. From 398 patients,
we excluded FH patients with normal LDL cholesterol levels at baseline (N=7),
were not on lipid lowering therapy (N=8), were only on ezetimibe monotherapy
(N=2), and FH patients who were pregnant (N=18). In total, 363 FH patients (186
women and 177 men) were included in the current study.
In 79% of the FH patients, a pathogenic mutation was identified. All patients
 included in the study provided written informed consent and completed a base-
line questionnaire. The response rate for the questionnaire was 100% and there
was no missing information. The questionnaire was developed in cooperation
with experts from the Cardio Vascular Genetic (CVG) team. Patients were asked
about the highest total cholesterol level ever registered. Additionally, they pro-
vided information regarding the date of initiating lipid lowering therapy as well
as the type of medications and the doses used. Subsequently, questions related
to side effects, as multiple choice of different types of side effects related to
the treatment use, were asked. Based on the number of reported side effects,
we made 3 categories of one, two, and three or more side effects. The influence
of side effects on quality of life was assessed using health status questionnaire
and graded on a scale comprising from none, some, or severe. 
Questions about adherence of medication, family history of premature CHD,
history of CVD, quality of life, as well as characteristics such as education and
lifestyle parameters including physical activity and risk factors such as smoking
and alcohol consumption were provided. High education was defined as type
of education (college or university). Alcohol consumption was defined as type
of alcohol (liquor, beer and wine) and amount of alcohol consumed per week.
Physical activity was defined as any type of exercise (walking, cycling, gardening,
sporting or other exercises) 30 minutes per day.
All information provided in the questionnaires was revalidated with the medical
records. Patient characteristics, including age, sex, body mass index, laboratory
values and blood pressure were abstracted from medical records.
All patients were carefully monitored annually at the lipid clinic by a specialized
vascular nurse. They received regular patient tailored education about their dis-
ease, lifestyle advices, benefits of using statins and the effect of treatment on
lipid profiles. Patients were asked in every visit how many times they deviated
from the regime according to the European guideline for the management of
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dyslipidaemias 4. Side effects were discussed and statins were changed when
necessary. Prescribing medication was reserved to the physician. 
During consultation, patients were physically examined to obtain the measures
of height, weight, and blood pressure. A fasting lipid blood sample was taken.
Hypertension was defined as blood pressure >140/>90 mmHg on more than 2
occasions or the use of a prescribed antihypertensive medication. Type II dia-
betes mellitus was diagnosed according to the World Health Organization
(WHO) criteria or the use of prescribed anti-diabetic medication 21. CVD was
defined as myocardial infarction, coronary artery bypass graft, percutaneous
transluminal coronary angioplasty, or ischemic cerebrovascular accident. The
majority of the patients (80%) completed the questionnaire directly after their
visit. Patients, who forgot to send back the questionnaire, were called by the
specialized nurse. Unanswered questions were completed during the following
visit. 
Lipid-lowering therapy
Lipid-lowering drugs were identified and classified at the level of the therapeutic
class (ie, statins, bile acid sequestrants, fibric acid derivatives, nicotinic acid
 derivatives, or other lipid-lowering drugs). 
Three main categories of statins (atorvastatin, rosuvastatin, simvastatin) were
created to include statins which were mostly used in the cohort. 
Treatment effectiveness
The treatment effectiveness included as the outcome measure in the current
study was reduction in total cholesterol (TC) levels after treatment with statins.
This was defined as: (1) percentage of TC reduction from baseline [decrease in
TC level (%) = (untreated TC – treated TC) / untreated TC]. This variable was
used as a continuous outcome; (2) ≥50% reduction in TC levels; a dichotomous
outcome variable with values of yes or no. Low-density lipoprotein (LDL) cho-
lesterol reduction to <2.6 mmol/l was not used as an outcome measures as it
comprised a very small group of patients in our cohort (N=35, 18.6% of women;
N=32, 18.1% of men). Our choice of the outcome measure was oriented towards
a clinically meaningful concept for both clinical practitioners and patients and
relates to the 2007 European Society of Cardiology/ European Atherosclerosis
Society (ESC/EAS) guidelines 4 as they were used at the time our study was es-
tablished.
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Statistical analyses
Descriptive statistics were performed to provide the full picture of baseline char-
acteristics. The values were presented as mean±Standard Deviation (S.D.) for
continuous variables and numbers (percentages) for dichotomous variables.
Chi-square tests were performed to assess differences in proportions and the
student t-test was used to assess differences in means. 
All the analyses were performed separately for women and men. We developed
multivariate linear regression models which included the variables that were sig-
nificantly associated with the continuous outcome in univariate analyses as well
as a priori defined predictors and confounders namely age, history of CVD, fam-
ily history of premature CHD, type of statins, maximum statin dose therapy, and
statin side effects. Different statins were included in the model as dummy vari-
ables for atorvastatin, rosuvastatin, and simvastatin with simvastatin as the ref-
erence category. We checked for possible nonlinearity in the association of the
variables with the outcome and for effect modification between age with treat-
ment effectiveness and with side effects by adding quadratic and interaction
terms respectively. Inclusion of the variables for the final model was determined
by backward stepwise elimination of the least significant variables until all vari-
ables in the model had a p-value ≤0.1. The analyses were performed using SPSS
software version 23 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp)
and R (3.2.3). Statistical significance was defined as P ≤0.05. 
Results 
General characteristics
Table 1 details the demographic characteristics of 363 FH patients (186 women
and 177 men) included in the study. Women consumed less alcohol and ad-
hered more frequently to a lipid lowering diet. Family history of premature CHD
was more prevalent among women. Women had higher levels of both untreated
and treated TC as well as treated LDL and high density lipoprotein (HDL) cho-
lesterol and lower levels of treated triglycerides. 
Lipid-Lowering Therapy
Of the patients using statins, the majority used atorvastatin (40.3% in women
and 50.8% in men, P=0.04), followed by rosuvastatin (with 23.1% in women and
18.6% among men) and simvastatin (with 33.3% in women and 28.2% among
men) (table 2).
Smaller proportion of women (64.5% in women and 75.7% in men, P=0.02) were
on maximum dose statin therapy; defined as 40 mg rosuvastatin, >40 mg ator-
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vastatin, 80 mg simvastatin. There were no gender differences in the adherence
to treatment as well as in the duration of statin use (table 2). 
Tolerability
Overall, side effects attributed to lipid-lowering therapy were reported by 57.2%
of women and 42.8% of men. The prevalence of patients reporting three or
more side effects was higher in women (24.8%) compared to men (19.7%), albeit
not statistically significant (table 2). Myalgia was the most common reported
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Table 1. Characteristics of FH patients, according to gender
Age (years), mean ±SD
BMI (kg/m2), mean ±SD
Current smokers, n (%)
Alcohol consumption, n (%)
Lipid lowering diet, n (%)
Physical activity, n (%)
Hypertension, n (%)
Diabetes, n (%)
Hyper-hypothyroidism, n (%)
History of CVD b, n (%)
Family history of premature CHD c, n (%)
High education, n (%)
FH signs, n (%) 
DNA mutation, n (%)
Untreated total cholesterol, mmol/L
Treated lipid profiles, mmol/L
Total cholesterol, mean ±SD
LDL cholesterol, mean ±SD
HDL cholesterol mean ±SD
Triglyceride, mean ±SD
Women 
n=186
45.9±14.7
26.2±4.8
29 (15.6)
108 (58.1)
180 (96.8)
135 (72.6)
32 (17.2)
7 (3.8)
8 (4.3)
25 (13.4) 
138 (74.2)
101 (54.3)
60 (32.3)
144 (77.4)
10.3±2.7
5.5±1.5
3.5±1.4
1.5±0.4
1.1±0.5
Men 
n=177
45±12.7
26.2±3.7
30 (16.9)
142 (80.2)
161 (91.0)
114 (64.4)
28 (15.8)
6 (3.4)
3 (1.7)
22 (12.4)
113 (63.8)
114 (64.4)
57 (32.2)
142 (80.2)
9.7±1.9
5.0±1.1
3.3±1.0
1.2±0.3
1.2±0.7
p a
0.51
0.99 
0.73
<0.01
0.02
0.09
0.72
0.90
0.15
0.77
0.03
0.50
0.99
0.51
0.02
<0.01
0.08
<0.01
0.03
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; FH, familial hypercholes-
terolemia; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number; SD, standard deviation.
a P-value for the difference between women and men. 
b CVD is defined as myocardial infarction, coronary artery bypass graft, 
percutaneous transluminal coronary angioplasty, or ischaemic cerebrovascular accident.
c Premature CHD is defined as a CHD event before the age of 55 (in men) or 60 (in women).
side effect among all side effects (reported by 60.2% of women and 53.4% of
men) (figure 1). No major side effects such as rhabdomyolysis or >3 times upper
limit of normal elevation of liver enzymes were reported. Women, compared to
men, reported twice as higher severe impact of statin therapy on their quality
Chapter 6
82
Table 2. Treatment characteristics for FH patients, according to gender 
Lipid lowering treatment
Atorvastatin, n (%)
Rosuvastatin, n (%)
Simvastatin, n (%)
Other statins b, n (%)
Adherence to medication >90%, n (%)
Statin use (years), mean±SD
High-intensity therapy c, n (%)
Treatment effectiveness
Decrease in untreated TC (%), mean±SD
≥50% decrease in total cholesterol, n (%)
LDL<2.6 mmol/l, n (%)
Side effects
Side effects, n (%)
no side effects
one side effect
two side effects
three or more side effects
ALT (U/L), mean±SD
AST (U/L), mean±SD
Creatine kinase (U/L), mean±SD
Effect of statin therapy on Quality of life, n (%)
none
some
severe
Women 
n=186
75 (40.3)
43 (23.1)
62 (33.3)
6 (3.2)
164 (88.2)
8.5±6.0 
120 (64.5)
43.9±15.4
75 (39.9)           
35 (18.8)
83 (44.6)
30 (16.1)
27 (14.5)
46 (24.8)
27±18.7
26.5±9.6
115.3±87.1
126 (67.7)
37 (19.9)
23 (12.4)
Men 
n=177
90 (50.8)
33 (18.6)
50 (28.2)
4 (2.3)
158 (89.3)
9.4±6.0 
134 (75.7)
46.7±14.0
87 (49.2)
32 (18.1)
89 (50.3)
29 (16.4)
24 (13.5)
35 (19.7)
41±21.8
31.2±10.4
150.8±85.5
131 (74.0) 
34 (19.2)
12 (6.8) 
p a
0.04
0.30
0.08
0.90
0.74
0.16
0.02
0.08
0.07
0.90
0.38
0.28
0.98
0.80
0.26
<0.01
<0.01
<0.01
0.09
0.19
0.87
0.07
LDL, low-density lipoprotein; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase;
FH, familial hypercholesterolemia, n, number; SD, standard deviation.
a P-value for the difference between women and men.
b other statins is included pravastatin and fluvastatin.
c High-intensity therapy is defined as Atorvastatin (>40 mg), Simvastatin (>40, 80 mg), Rosuvastatin (40 mg).
of life due to side effects (12.4% vs 6.8%, P=0.07). (table 2)
Figure 2 demonstrates the prevalence of the most common reported side effect
(myalgia) for the three most used statins (atorvastatin, rosuvastatin, and simva 
statin) among women and men. While myalgia was reported by 53.5% of women
and 33.3% of men receiving rosuvastatin, 37,3% of women and 20.0% of men
on atorvastatin, and 16.1% of women and 32,0% of men on atorvastatin treat-
ment reported this side effect. 
Reduction in TC levels
The mean percentage decrease in TC level was 43.9% in women and 46.7% in
men (P=0.08). Overall, 39.9% of women and 49.2% of men reached ≥50% re-
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Figure 1. Types of statin side effects among FH patients on lipid
lowering therapy, by gender.
Some patients reported more than one side effect
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Figure 2. Prevalence of myalgia for different statins by gender
Women
Men
* Prevalence of myalgia as the most common reported side effect for three different statins
(atorvastatin, rosuvastatin, simvastatin) among women and men.
Statins
atorvastatin rosuvastatin simvastatin
100
80
60
40
20
0
Tr
ea
tm
en
t 
ef
fe
ct
iv
en
es
s 
(%
)
Figure 3. Treatment effectiveness for different statins by gender
Women
Men
* Treatment effectiveness (reduction in untreated total cholesterol levels ≥50% for three
different statins (atorvastatin, rosuvastatin, simvastatin) among women and men.
Statins
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duction in TC levels (P=0.07). Reduction in LDL cholesterol <2.6 mmol/l was
achieved by only 18.6% of women and 18.1% of men. There were no gender
differences in the adherence to treatment as well as in the duration of statin use
(table 2). The untreated TC levels reduced in 49.3% of women receiving ator-
vastatin and 60.6% of men receiving rosuvastatin whereas simvastatin was the
least potent statin in reducing TC levels (figure 3). 
Results of the univariate linear regression analysis for the association between
reduction in TC levels (a continuous outcome defined as percentage decrease
in TC) with different patient characteristics for women and men are shown in
Supplemental table 1. The results of the ordinary least squares regression model
predicting percentage change in TC levels from baseline are shown in table 3.
Table 3. Associations between determinants and cardiovascular events
Age
BMI
Smoking
Alcohol consumption
Lipid lowering diet
Physical activity
Hypertension
Diabetes
History of CVD b
Family history of premature CHD c
High-intensity therapyd
Side effects
Women (n=180) a
B (95%CI)
0.21 (0.06; 0.36)
-0.03 (-0.49; 0.43)
-3.56 (-9.59; 2.47)
-1.97 (-6.46; 2.53)
-0.53 (-12.92; 11.86)
1.99 (-2.94; 6.92)
6.52 (0.78; 12.25)
-2.63 (-14.13; 8.87)
4.61 (-1.90; 11.12)
5.68 (0.68; 10.67)
5.50 (0.85; 10.15)
-3.90 (-8.32; 0.53)
p
0.01
0.89
0.25
0.39
0.93
0.43
0.03
0.65
0.16
0.03
0.02
0.08
Men (n=173) a
B (95%CI)
0.35 (0.20; 0.51)
0.12 (-0.44; 0.68)
-7.01 (-12.49;-1.53)
-6.12 (-11.28;-0.96)
13.18 (6.26; 20.01)
0.98 (-3.38; 5.34)
4.71 (-0.99; 10.41)
9.36 (-1.95; 20.66)
7.18 (1.01; 13.34)
5.44 (1.19; 9.69)
3.82 (-1.13; 8.78)
-0.47 (-4.64; 3.70)
p
<0.01
0.66
0.01
0.02
<0.01
0.66
0.11
0.10
0.02
0.01
0.13
0.82
Beta coefficient (95% confidence interval) shows the crude (unadjusted) association between each patient’s
characteristic and treatment effectiveness (defined as a continuous outcome of percentage reduction in total
cholesterol levels).
BMI; Body Mass Index; CHD; coronary heart disease; CVD; cardiovascular disease; 
FH; familial hypercholesterolemia; n; number.
a 10 FH patients (6 women and 4 men) receiving other statins (pravastatin or fluvastatin) were excluded from
this analysis as we made 3 main categories to include statins which were mostly used in our cohort (atorvas-
tatin, rosuvastatin, and simvastatin).
b CVD is defined as myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary
angioplasty, or ischaemic cerebrovascular accident.
c Premature CHD is defined as a CHD event before the age of 55 (in men) or 60 (in women).
Chapter 6
86
Among women, the variables (Beta; 95% confidence interval) positively associ-
ated with the outcome were age (0.22;0.07,0.37), treatment with atorvastatin
(6.64;1.58,11.70), with rosuvastatin (6.38;0.45,12.31), and maximum dose statin
regimen (6.62;2.02,11.21). Presence of side effects (-5.37;-9.85,-0.89) was in-
versely associated with the outcome among women. Among men, adherence
to the lipid lowering diet (8.28; 1.83,14.72) and addition of ezetimibe to ator-
vastatin (6.95;2.80,11.11) and to rosuvastatin (9.08;2.66,15.49) were positively as-
sociated with the outcome and smoking (-5.88;-10.90,-0.86), alcohol
consumption (-6.61;-11.23,-1.99) showed to be inversely associated with the out-
come. 
Discussion 
In the current study, we report differences between women and men in lipid
profile, lipid lowering therapy, statin adverse effects, and factors associated with
treatment effectiveness in a well-defined cohort of FH patients. Despite higher
TC levels at baseline, women were less likely to receive maximum therapy.
 Nevertheless, treatment effectiveness was not significantly lower for women
compared to men. Women were more likely to experience three or more side
effects due to statins and a larger proportion of them reported severe impact
of statin therapy on their quality of life. Importantly, presence of side  effects was
inversely associated with treatment effectiveness among women. On the other
hand, behavioral factors such as smoking, alcohol consumption, and adherence
to lipid lowering diet were associated with treatment effectiveness in men.  
In contrast with some studies, 22, 23 we observed higher TC levels for women at
baseline in our study. Nevertheless, women appeared to be less likely to receive
maximum dose statin treatment. This finding is in line with the report from the
SAFEHEART study that found female sex to be independently associated with
less likelihood of the use of high-intensity statins 19. Due to the paucity of data
with regard to gender differences in treatment with statins, the effectiveness
and benefits of statin therapy for primary CVD prevention among women in the
general population has been controversial 24-27. To overcome the gender bias
in the management of women, a secondary analyses of the PROVE IT-TIMI 22
trial provided robust evidence regarding the safety, efficacy, and the clinical im-
pact of intensive statin therapy to reduce the CVD events among women 28.
These results, in line with other trials regarding the efficacy of intensive statin
treatment in CVD prevention among high risk women, 29 reinforces the value of
intensive statin therapy among women with FH. Despite lower proportion of
women receiving maximum therapy in our study, treatment effectiveness was
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not significantly lower for women compared to men which could suggest that
women have a more robust TC reduction on lower statin doses compared to
men.
Extensive clinical evidence supports the efficacy, safety, and tolerability of statin
treatment for prevention of CVD  7, 13. However, there is a paucity of information
in the area of statin-related adverse effects in adult FH patients. A previous study
on predicting non-adherence in patients with FH, has cited 27% side effects 8.
Another study reported only a total of 55 FH patients, out of 781, to have dis-
continued medication. However, 45% of this withdrawal was due to statin ad-
verse events 30. The most commonly reported side effect of statins was myalgia.
While several meta-analyses of randomized clinical trials comparing statins to
placebo have shown increased myalgia in patients receiving statins, the evi-
dence regarding myalgia is rather mixed 31. In our study, side effects, mainly
myalgia, were reported by a large proportion of patients; 33.9% of women and
26.0% of men. While there was no gender difference in the overall percentage
of patients who reported any side effect, women were more likely to report hav-
ing experienced three or more side effects. Women and men on simvastatin
treatment reported the smallest proportion of myalgia, while the largest pro-
portion was among rosuvastatin users in both genders. Compared to men, a
larger proportion of women in our study reported a severe effect on their quality
of life associated with lipid-lowering medications. Importantly, while serious or
fatal statin adverse events are rare, common side effects such as myalgia might
affect the adherence to treatment in long-term. 
International guidelines consider FH patients to be at high risk for CVD 3-6, 32.
To prevent CVD, intensive lipid management in women and men with FH is
therefore of paramount importance. According to the previous studies and 2007
ESC/EAS guidelines, treatment recommendations included the use of high po-
tency statins titrated to optimally achieve 50% reduction in total and LDL cho-
lesterol levels or treated TC of <5.0 mmol/l and treated LDL cholesterol level
of <2.6 mmol/l 4. Although the use of maximum treatment regimen has been
considered effective for attaining these treatment levels 33 only around 18% of
women and men in our FH cohort reached LDL cholesterol levels <2.6 mmol/l
and approximately half of the patients achieved the 50% reduction in baseline
TC levels. The small percentage of FH patients attaining the LDL treatment goal
in our study is in line with the report from a cross-sectional study of FH patients
in the Netherlands 9. Nevertheless, the high adherence rates of our FH patients
(87.2% of women and 89.3% of men) can be a reflection of patients’ self-man-
agement and the availability of a dedicated FH care in our clinic. 
Thus far, gender-related differences in the effectiveness of lipid lowering therapy
and its associated factors have not been adequately clarified. Only few studies
have compared the effects between women and men and none have assessed
gender differences among FH patients. In our cohort of FH patients, we showed
gender differences in the effectiveness of different types of statins. Among the
three main categories of statin in our study, atorvastatin and rosuvastatin were
significantly associated with treatment effectiveness in women while addition
of ezetimibe to the statin treatment led to the treatment effectiveness in men.
Importantly, statin side effects were inversely associated with achieving the de-
sirable clinical outcomes in women. This highlights the need to investigate gen-
der related differences in the role of pharmacokinetics and pharmacodynamics,
as well as the impact of pharmacogenetics on both. Behavioral factors such as
smoking, alcohol consumption, and adherence to lipid lowering diet were in-
versely associated with treatment effectiveness in men but not in women. These
results underscore the need for promotion of healthy lifestyle through counsel-
ing programs to further emphasize the central role of lifestyle as the foundation
to benefit from cholesterol-lowering therapy. 
The results of our study must be considered within the context of its strengths
and limitations. To our knowledge, our study is the first to investigate gender
differences in lipid profile, lipid lowering therapy, statin side effects, as well as
treatment effectiveness and its associated factors in FH patients. We had access
to a well-defined cohort of FH patients with detailed information regarding pa-
tients’ characteristics, treatment regimens, and side effects. Our unique data-
base is based on data obtained from clinical practice and questionnaires.
However, it represents a single center with a limited number of patients and our
results, therefore, need to be validated in other FH patient populations. 
Conclusion 
We reported gender differences in lipid profile, lipid lowering therapy, statin
adverse effects, and factors associated with treatment effectiveness in a well-
defined cohort of patients with FH. Our study highlights the lower likelihood
for women to receive high-intensity therapy despite their poorer baseline lipid
profile and emphasizes the negative impact of statin side effects on achieving
the desirable clinical outcomes among women. 
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Abstract 
Background
Despite optimal lipid-lowering therapy, a minority of patients with familial hy-
percholesterolemia (FH) reach LDL-cholesterol (LDL-C) target goals. In random-
ized trials Proprotein convertase subtilisin/Kexin 9 (PCSK9) inhibitors led to
impressive LDL-C reductions and a favorable safety profile. However, data about
the efficacy and safety outside clinical trials is not available yet. 
Objective
To describe efficacy and side effects of PCSK9 inhibitors in FH patients in clinical
practice.
Methods
Registry of all consecutive FH patients who started with a PCSK9 inhibitor at a
lipid clinic of a university hospital.
Results: We analyzed 83 FH patients (79 heterozygous FH (heFH) (65 with a ge-
netically confirmed heFH, 14 with clinical heFH and 4 homozygous FH (hoFH)),
with a mean age of 55.1±11.6 years. Treatment with a PCSK9 inhibitor resulted
in an additional reduction of 55%±21% in mean LDL-C levels. Patients with heFH
had more LDL-C decrease than patients with hoFH (56% vs 38%). Patients using
ezetimibe monotherapy because of statin-intolerance (n=24, 29%) had less 
LDL-C decrease compared to patients who concurrently used statin therapy
(47% and 58%, p=0.03). 
Side effects of PCSK9 inhibitors were reported by 32 patients (39%). Flu-like
symptoms (n=12) and injection site reactions (n=11) were most frequent. Seven
patients (8%) discontinued treatment, five because of side effects, two because
of non-response. 
Conclusion
Our initial experience of PCSK9 inhibition in FH patients in a clinical setting
showed comparable reduction in LDL-C levels but more side effects compared
to clinical trials. 
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Introduction
Familial hypercholesterolemia (FH) is the most common autosomal dominant
disorder of the lipid metabolism, mainly caused by gene mutations in the low
density lipoprotein receptor (LDLR) 1. Based on an estimated prevalence of
1:244 persons, the expected number of FH patients in the Netherlands is 70.000
2. FH is characterized by elevated plasma levels of LDL-Cholesterol (LDL-C) and
is associated with an increased risk of premature cardiovascular disease (CVD)
3, 4. However, timely initiation of lipid lowering therapy (LLT) in combination with
lifestyle modification is very effective for CVD prevention in these patients 5-7.
Last decades more potent statins have been developed and the addition of
ezetimibe to LLT resulted in further improved cardiovascular outcomes 8, 9. How-
ever, only a minority of FH patients reaches LDL-C treatment goals even with
maximum LLT 10-12.
Recently a new class of lipid-lowering therapy, Proprotein Convertase Subtilisin
/ Kexin 9 (PCSK9) inhibitors, has been developed for those high risk patients
not reaching LDL-C target despite maximum tolerated LLT. Currently two PCSK9
inhibitors are available: evolocumab and alirocumab. In randomized controlled
trials, these monoclonal antibodies show a LDL-C reduction up to 60%. In gen-
eral, PCSK9 inhibitors are well tolerated in these trials with most common ad-
verse events reported by ≥5% in patients treated with alirocumab or
evolocumab, occurring more frequently than with placebo 13-16. However, it is
important to ensure that data from clinical trials apply to real-life settings as
well, especially when it concerns long term safety. This will improve the appli-
cability of the trial evidence to daily practice. 
The goal of our study was to evaluate our initial clinical experience regarding
efficacy and side effects of PCSK9 inhibitors in FH patients outside clinical trials. 
Patients and methods
Participants
Patients with FH were recruited from the out-patient clinic specialized in (inher-
ited) lipid disorders of Erasmus MC. The diagnosis heterozygous FH (heFH) was
based on either the identification of an FH causing pathogenic mutation in the
LDLR, APOB or PCSK9 gene or in those without an FH mutation (genetic heFH),
a clinical diagnosis of FH was made by a Dutch Lipid Clinic Network score of
≥6 representative of probable or definite FH (clinical heFH) 17, 18. Homozygous
FH (hoFH) was defined as either true homozygous FH (two similar LDLR or APOB
mutations), compound heterozygous FH with two different LDLR or two different
APOB mutations, or double heterozygous as one LDLR and one APOB mutation.
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The following patients with confirmed FH ≥18 years were considered eligible
for treatment with PCSK9 inhibitors in our institute because of very high risk of
CVD defined as:
1. HeFH patients without CVD events, on maximum tolerated statin and eze-
timibe therapy with LDL-C >3.5 mmol/L (135 mg/dL).
2. HeFH patients with CVD events, on maximum tolerated statin and ezetimibe
therapy with LDL-C >2.5 mmol/L (100 mg/dL).
3. HoFH patients who did not carry two LDLR negative mutations on maximum
tolerated statin and ezetimibe therapy, with LDL-C >3.5 mmol/L (135 mg/dL)
without CVD events or LDL-C >2.5 mmol/L (100 mg/dL) with history of CVD
events.
4. FH patients with documented statin intolerance defined as statin-associated
myalgia for at least three different statins in accordance with the flow chart
described by EAS/ESC consensus and in combination with ezetimibe
monotherapy with LDL-C >3.5 mmol/L (135 mg/dL) without CVD events or
LDL-C>2.5 mmol/L (100 mg/dL) with history of CVD events 19. 
All patients fulfilled the Dutch criteria for reimbursement of PCSK9 inhibitors.
In case of FH these criteria are having an LDL-C >2.5 mmol/L (100 mg/dL) with-
out CVD events or an LDL-C >1.8 mmol/L (70 mg/dL) with a history of CVD
events, despite optimal statin treatment and ezetimibe 20.
Patients started with a PCSK9 inhibitor (evolocumab 140 mg subcutaneously
every two weeks (heFH patients) or 420 mg subcutaneously every two weeks
(hoFH patients) or alirocumab 75 mg or 150 mg subcutaneously every two weeks
(heFH patients)) between 1 May 2016 and 14 October 2016 as part of clinical
care. There was no preference for either evolocumab or alirocumab. All patients
had at least 2 PCSK9 inhibitor subcutaneous injections between baseline and
on-treatment measurements.
According to the Medical Ethical Research Committee this study was not subject
to the Medical Research involving Human Subjects Act. We only used data of
patients, who provided written consent for research and anonymous publication
of their clinical information.
Study design
All patients were treated at the outpatient lipid clinic by the cardiovascular ge-
netic team consisting of a lipidologist, a nurse practitioner, a fellow vascular
medicine and two nurses specialized in family counselling according to the
 European guideline for the management of dyslipidaemias 21. 
The follow-up started at the date patients received instructions of how to use
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the auto-injector and administrated the first injection PCSK9 inhibitor subcuta-
neously. The effects on lipoprotein profile, side effects and adherence were
monitored. Blood (lipoproteins, glucose and liver tests) was measured before
and after 6 weeks when patients had an regular appointment at the out-patient
clinic. Side effects, injection-site reactions and adherence of lipid lowering the -
rapy was systematically discussed during each consultation.
Clinical data such as LDLR, APOB and or PCSK9 gene mutations, plasma
lipoprotein levels (total cholesterol, triglycerides, LDL-C, apolipoprotein B and
HDL-cholesterol), liver tests (ASAT, ALAT, gamma-glutamyl-transferase), current
and previous LLT, CVD events, adherence, side effects, injection site reactions
and general characteristics (age, sex and body mass index (BMI)) were collected
from the patients’ files and entered in a database.
High-intensity statin was defined as atorvastatin (40-80mg), rosuvastatin (20-
40mg) or simvastatin 80mg with ezetimibe. Moderate intensity statin was de-
fined as atorvastatin (10 to <40mg), rosuvastatin (5 to <20mg) or simvastatin
(20-40mg), pravastatin (40mg), fluvastatin (40-80mg) and low intensity as ator-
vastatin (<10mg), rosuvastatin (<5mg), simvastatin (<20mg), pravastatin (<40mg)
or fluvastatin (<40mg) 22.
Maximum tolerated LLT was defined as the maximum dose of statins to which
patients could adhere without unbearable side effects in combination with eze-
timibe. Statin intolerance was defined as documented unbearable side effects
of at least three statins including low dose statins on non-daily basis 19. 
Smoking was defined by start and stop dates from the patients file. Smoking
cessation was defined as stopped >1 year. Overweight was defined as BMI>25
kg/m2. Hypertension was defined as blood pressure >140/>90 mmHg on more
than two occasions or the use antihypertensive medication 23. Type 2 diabetes
mellitus was diagnosed according to the American Diabetes Association or the
use anti-diabetic medication 24. CVD was defined as having been diagnosed
with either myocardial infarction, angina pectoris confirmed by a cardiologist,
coronary artery bypass grafting or percutaneous coronary intervention, transient
ischemic accident or stroke diagnosed by a neurologist or a peripheral arterial
disease diagnosed by vascular surgeon 25. These events were collected from
the patients' medical records. 
Statistics 
All data were analysed anonymously using SPSS Statistics for Windows, version
23.0 (IBM Corp.). Dichotomous variables are reported as numbers and percen -
tages. Continuous variables are presented as mean±standard deviation (SD) or
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median and interquartile range (IQR). The Shapiro-Wilks test was used to assess
whether data were normally distributed. Differences between subgroups of FH
patients were analysed by chi-square, Student’s t-test and paired t-test as ap-
propriate. For all tests a p-value less than 0.05 was considered statistically sig-
nificant.
Results 
A total of 83 FH patients (47% women, mean age 55.1±11.6 years) started either
evolocumab (n=52) or alirocumab (n=31) in addition to maximal tolerated LLT.
The baseline characteristics of the FH patients according to PCSK9 inhibitor are
shown in table 1.
Fifty patients used evolocumab 140 mg subcutaneously every two weeks and
two hoFH patients used evolocumab 420 mg every two weeks. Twenty-nine pa-
tients used alirocumab 150 mg subcutaneously every two weeks and two pa-
tients alirocumab 75 mg subcutaneously every two weeks. The majority (83%)
of the FH patients were carrier of a pathogenic mutation in the LDLR (73%) or
APOB (10%) gene. The diagnosis of heFH was genetically (78%) or clinically
(17%), 5% had hoFH. Sixty percent of our patients had a history of CVD, mainly
coronary artery disease (52%). Other cardiovascular risk factors were frequent:
especially overweight (66%), hypertension (40%) and diabetes mellitus (13%).
On the other hand only a minority (5%) were current smokers. Seventy-one per-
cent of the patients used statins in combination with ezetimibe and half (49%)
of the statin-users were treated with high-intensity statin therapy, 29% used eze-
timibe monotherapy because of statin intolerance. 
At baseline the mean total cholesterol level was 6.9±2.3 mmol/L (267±89 mg/dL)
and LDL-C 5.0±2.1 mmol/L (193±81 mg/dL). HeFH patients had a mean LDL-C
of 4.9±2.1 mmol/L (190±81 mg/dL) and hoFH patients had, as expected, a
markedly higher mean LDL-C of 7.4±4.3 mmol/L (286±166 mg/dL). The mean
time between baseline levels and those during PCSK9 inhibitor treatment was
41±48 days. 
Efﬁcacy
The addition of PCSK9 inhibitor therapy resulted in a mean LDL-C decrease of
55%±21% and a median LDL-C decrease of 58%, IQR 43%-72% in the total pop-
ulation; in heFH patients a mean LDL-C decrease of 56%±20% and a median
LDL-C decrease of 58%, IQR 43%-72% and in hoFH patients a mean LDL-C de-
crease of 38%±32% and a median LDL-C decrease of 47%, IQR 5%-62% was ob-
served.
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Table 1. General characteristics of patients with FH before starting PCSK9
inhibitors at baseline
Age (years) mean±SD
Women, n(%)
Caucasian, n(%)
History of CVD, n(%)
Cardiovascular risk factors, n(%)
Ever smoker
Current smoker
BMI mean±SD
History of hypertension
DM type 2
FH 
• Heterozygous
• Homozygous
• Clinical 
Lipid lowering therapy, n(%) 
• Statin use
• High intensity
•  Moderate intensity
• Low intensity
• Ezetimibe 
• Ezetimibe monotherapy
Lipid values, mean±SD
• Total cholesterol (mmol/l)*
• LDL cholesterol (mmol/l)*
• HDL cholesterol (mmol/l)*
• Triglyceride (mmol/l)†
• Apo B (g/L)
• Glucose (mmol/l)
Liver tests, mean±SD
• ASAT (U/L)
• ALAT (U/L)
• Gamma GT (U/L)
Baseline
n=83
55.1±11.6
39 (47)
76 (92)
50 (60)
39 (47)
4  (5)
27.3±4.0
33 (40)
11 (13)
83 (100)
65 (78)
4  (5)
14 (17)
59 (71)
41 (49)
14 (17)
4  (5)
83 (100)
24 (29)
6.9±2.3 
5.0±2.1 
1.4±0.6 
1.7±1.2 
1.5±0.6 
5.8 ±1.3
27.5±9.1
30.2±13.9
32.2±19.4
LDL=low density lipoprotein; HDL= high density lipoprotein; CVD= cardiovascular disease; BMI= body
mass index; DM= diabetes mellitus; FH=familial hypercholesterolemia; ASAT= aspartate aminotransferase;
ALAT= alanine aminotransferase; Gamma GT= gamma glutamyl-transferase; LLT= lipid lowering therapy;
FH=familial hypercholesterolemia
*1 mmol/l=39 mg/dl † 1mmol/l=89 mg/dl
No difference between evolocumab and alirocumab in LDL-C reduction was
observed. Genetic heFH patients had less LDL-C decrease compared to pa-
tients with clinical heFH (53% vs 67%, p<0.001). The four hoFH patients showed
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Table 2. Effect of PCSK9 inhibitors after 6 weeks follow-up
PCSK9 inhibitors, n(%)
Evolocumab
Alirocumab
Lipid values, mean±SD
• Total cholesterol (mmol/l)*
• LDL cholesterol (mmol/l)*
• HDL cholesterol (mmol/l)*
• Triglyceride (mmol/l)†
• Apo B (g/L)
Glucose (mmol/l)
LDL-C decrease (% mean±SD)
LDL-C ≤1.0 mmol/l*
LDL-C by treatment goal, n(%)
• Primary prevention, LDL-C ≤2.5 mmol/l*
• Secondary prevention, LDL-C ≤1.8 mmol/l*
Liver tests, mean±SD
• ASAT (U/L)
• ALAT (U/L)
• Gamma-GT (U/L)
Reactions of PCSK9 inhibitors, n(%)
Side effects 
Injection site reaction
Quit PCSK9 inhibitors
• Side effects
• Non responders
Total
n=83 
52 (63)
31 (37)
4.3±2.4
2.4±2.1
1.4±0.4
1.4±0.9
0.9±0.6
6.1±2.0
54.9±20.6
14 (17)
48 (58)
18 (55)
30 (60)
27.1±13.4
32.2±29.3
28.5±10.2
32 (39)
11 (13)
7  (8)
5  (6)
2  (2)
HeFH/
Clinical FH
n=79
49 (62)
30 (38)
4.1±1.9
2.3±1.7
1.4±0.4
1.5±0.9
0.8±0.5
6.2±1.9
55.8±19.8
14 (18)
47 (60)
18 (23)
29 (37)
26.5±12.6
31.0±27.8
29.0±11.4
HoFH
n=4
3 (75)
1 (25)
7.2±6.5
5.9±5.5
1.0±0.3
0.9±0.3
1.8±1.8
5.2±0.3
37.8±31.5
0
1 (25)
0
1 (25)
34.3±11.8
30.3±10.6
28.5±12.0
LDL=low density lipoprotein; HDL= high density lipoprotein; ASAT= aspartate aminotransferase; ALAT=
alanine aminotransferase; Gamma GT= gamma glutamyl-transferase 
*1 mmol/l=39 mg/dl † 1mmol/l=89 mg/dl.
an LDL-C decrease of 38% (figure 1). Three hoFH patients of whom it was known
that they carried ≥1 defective LDLR mutation, showed 50% LDL-C reduction but
one hoFH patient with a mutation of unknown effect on LDLR activity did not
have any LDL-C reduction. Therefore, we concluded that this patient had no or
little residual LDLR function and PCSK9 inhibitor therapy was discontinued. Pa-
tients with statin-intolerance had less LDL-C decrease compared to patients
who used PCSK9 inhibitors in addition to statin therapy (47% vs 58%, p=0.03).
No differences were observed in liver tests or glucose before and after addition
PCSK9 inhibitors. 
The treatment goal for primary prevention of LDL-C ≤2.5 mmol/L (100 mg/dL)
was achieved in 55% of patients without CVD, and the secondary prevention
target of LDL-C ≤1.8 mmol/L (70 mg/dL) in 60% of the patients who were known
Proprotein convertase subtilisin/Kexin 9 inhibition in patients with familial hypercholesterolemia: initial clinical experience
101
Table 3. Patient reported side effects of PCSK9 inhibitors 
Any
Flu like symptoms
Neurological
Abdominal symptoms
Nasopharyngitis
Allergic skin reactions
Myalgia/joint pain
Headache 
Fatigue
Eye irritation
Anxiety attacks
Dysarthria
Flushes
Hoarseness
Discontinuation
Injection site reactions, n(%)
Any
Hematoma’s
Redness
Painful injection
Swelling
32 patients (39%)
52 
12 (14)
8  (10)
6  (7)
4  (5)
4  (5)
4  (5)
4  (5)
3  (4)
3  (4)
1  (1)
1  (1)
1  (1)
1  (1)
7  (8)
11 patients (13%)
16
4  (5)
2  (2)
6  (7)
4  (5)
with CVD. In total 58% of the patients were on-target after addition of PCSK9
inhibitor therapy. Fourteen patients (17%) reached LDL-C levels <1.0 mmol/L
(39 mg/dL) (table 2). The lowest LDL-C level measured was 0.31 mmol/L (12
mg/dL), this patient with clinical heFH had a LDL-C decrease of 91%. 
On the other hand, 11% (n=9) were hypo- or non-responders defined as a LDL-
C decrease ≤25%. Eight of the nine hypo-responders were heFH patients with
a pathogenic mutation. They were of similar age and sex compared to the nor-
mal responders. In two patients no reduction of LDL-C was observed. One heFH
patient with a genetic mutation of the LDLR gene did not respond to PCSK9 in-
hibitor therapy. The other one was the aforementioned hoFH patient. 
Figure 1. Waterfall plot of LDL-C decrease of PCSK9 inhibitors in 
79 heterozygous FH patients (each bar represent one patient).
Figure 2. The effect of six weeks treatment with PCSK9 inhibitors according
to FH subgroup (HeFH genetic, HeFH clinical and HoFH).
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Adherence and side effects
All patients were able to use the auto-injector without any problems. Remem-
bering the unusual interval of administration of the PCSK9 inhibitor every two
weeks was mainly implemented through reminders on mobile phone and cal-
endars by patients themselves. All patients confirmed that they were absolute
adherent in the use of the PCSK9 inhibitor. Two patients reported technical
problems with the injector.
One or more side effects (n=52) of PCSK9 inhibitors were reported by 32 pa-
tients (39%) after an average of 6 weeks. Most often flu-like symptoms (14%) in
the first days after administrating and abdominal symptoms (7%) were men-
tioned. Neurological symptoms were reported by 8 (10%) patients, they all re-
ported more than one central or other neurological side effect. Most common
were: forgetfulness (n=5), dizziness (n=4), , blurred vision (n=4), confusion (n=2)
and depressive mood (n=2). Patients with statin intolerance had significant less
side effects (21 % vs 46%, p=0.05) compared to patients who used statins. One
or more injection site-reactions were reported by 11 patients (13%), ranging
from injection pain (7%) to hematomas (5%) and swellings (5%) on the skin.
Seven patients (8%) discontinued treatment; five because of side effects, two
patients because of non-response (table 3).
Discussion
We demonstrated that in clinical setting, addition of PCSK9 inhibitors to maxi-
mum tolerated LLT showed a similar LDL-C reduction as the randomized clinical
trials. The treatment goals of LDL-C ≤2.5 mmol/L (100 mg/dL) for primary and
LDL-C ≤1.8 mmol/L (70 mg/dL) for secondary prevention were achieved by 55%
and 60% of the patients respectively. However, side effects, especially flu-like
symptoms, and injection site-reactions were reported more often compared to
clinical trials.
Despite statin-ezetimibe combination therapy, the majority of FH patients fail
to attain LDL-C treatment targets. In the Netherlands LDL-C treatment goals
are achieved by only 20% of the FH population 10, 11. Therefore the introduction
of PCSK9 inhibitors with its significant LDL-C lowering potential is an attractive
additional treatment option for these patients. 
The mean LDL-C decrease in our FH population was comparable with random-
ized controlled trials which studied efficacy of PCSK9 inhibitors in FH patients
14, 15. The RUTHERFORD I and II randomized heFH patients on stable statin ther-
apy to evolocumab 140 mg (every two weeks) /420 mg (every four weeks) or
evolocumab 350 mg (every two weeks) /420 mg (every four weeks) versus
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placebo and demonstrated a 43%-55% and 60%-66% reduction LDL-C levels
respectively 26, 27. The ODYSSEY FH1 and FH2 trials compared alirocumab 150
mg subcutaneously every two weeks to placebo in heFH patients in addition to
high-intensity statin therapy with or without ezetimibe. After 24 weeks a LDL-C
reduction of 58% and 51% was observed in the two trials respectively 28. Among
heFH patients with LDL-C levels >5.2 mmol/L (201 mg/dL) despite maximum
tolerated LLT, the ODYSSEY HIGH FH study showed an LDL-C reduction of 46%
after 12 weeks alirocumab 150 mg subcutaneously every two weeks versus
placebo 14. The LDL-C baseline levels of the ODYSSEY HIGH FH study are com-
parable to the baseline levels of our FH patients, who showed a slightly higher
decrease in LDL-C. 
None of the clinical trials have so far compared the efficacy of treatment among
FH patients with and without genetic mutation. In our study, patients with heFH
with pathogenic mutations in LDLR or APOB gene had less LDL-C reduction
compared to patients with clinical heFH. While we cannot fully explain this find-
ing, one might speculate that patients with genetic heFH might have a lower
expression of LDLR compared to patients with clinical heFH. 
Evolocumab is the only PCSK9 inhibitor registered for hoFH patients. The
TESLA-B showed that the efficacy of evolocumab 420 mg was dependent on
LDLR residual function. While patients with two defective alleles had a 32% LDL-
C reduction, in patients with one defective and one null LDLR allele only 21%
reduction was observed and patients without LDLR residual function showed
no LDL-C reduction. This study therefore provided the evidence that the pres-
ence of a functional LDLR is essential for the mechanism of action of PCSK9 in-
hibitors. The 3 hoFH patients of our cohort with at least one defective LDLR
mutation had a 50% LDL-Creduction which is a larger decrease than observed
in the TESLA-B study. 
Twenty-four percent of our patients used ezetimibe monotherapy because of
documented statin intolerance. Three trials have studied the effect of PCSK9
inhibitors vs ezetimibe in patients with statin intolerance. The ODDESSEY AL-
TERNATIVE compared alirocumab versus ezetimibe. In this study, patients
started with 75 mg and if LDL-C target was not achieved after 8 weeks, the dose
was increased to 150 mg. The GAUSS-2 and GAUSS-3 studies compared
evolocumab 140 mg (every two weeks) and 420 mg (every four weeks) versus
ezetimibe. These trials demonstrated an LDL-C reduction of 45%-56% in pa-
tients treated with PCSK9 inhibitors and of 17% in patients treated with ezeti -
mibe 29-31. Unlike these trials, our patients with statin-intolerance all used
ezetimibe mono-therapy according to the Dutch reimbursement criteria. We
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observed a 47% reduction LDL-C in our patients which seems comparable to
the trials in patients with statin-intolerance but is lower than patients who con-
comitantly used statins. This underscores the importance of adherence to statin
therapy during PCSK9 inhibitor treatment.
Fourteen patients (17%) reached LDL-C values <1.0 mmol/L (39 mg/dL). These
very low LDL-C levels are new to most clinicians and have not been encountered
before the use of PCSK9 inhibitor therapy. Recently it was shown that extremely
low levels of LDL-C of <0.4 mmol/L (16 mg/dL) do not affect vitamin E and
steroid hormone metabolism 32. 
On the other hand 42% of the patients did not reach target levels despite PCSK9
inhibitors. This group was predominantly composed of hypo-responders and
patients with statin-intolerance who had inadequate LDL-C decrease. This un-
derscores that despite their high efficacy, PCSK9 inhibitors are not the solution
for all FH patients.
In the randomized trials, injection-site reactions were reported on average in
6% (range 0-12%),were similar in patients who used a PCSK9 inhibitor and those
on placebo, and did not result in discontinuation of the drug. In our study, in-
jection-site reactions were observed more often (13%) than the percentage re-
ported in the trials. However, none of the patients stopped the medication
because of injection site reactions. 
The randomized controlled trials studying PCSK9 inhibitors showed a very
favourable safety profile 33. In the meta-analysis of 17 trials studying PCSK9 in-
hibitor therapy the only side effects reported more frequently in patients ran-
domized to PCSK9 inhibitors vs placebo were neurocognitive adverse events
(OR 2.34; 95% CI 1.11-4.93). In the five PCSK9 randomized controlled trials in
FH patients, side effects were comparable to controls, with most common re-
ported side effects being nasopharyngitis (11%) and influenza (8%) 14, 26-28. In
the RUTHERFORD I study, neurological disorders were reported by 5% patients
versus 11% controls 26. A recent press release announced that the EBBING-
HAUS trial showed no effect on cognitive function in patients randomized to
evolocumab compared to placebo 34. In our study PCSK9 inhibitors were in gen-
eral well tolerated. However, side effects of flu-like symptoms, neurological
symptoms and abdominal symptoms were reported more frequently compared
to the heFH trials. For clinicians prescribing PCSK9 inhibitors, it is important to
recognize that patients report side effects more often compared to the clinical
trials. However only a minority of the patients experiencing side effects discon-
tinued the drug. It should be noted, however, that our patients used PCSK9 in-
hibitors for a short period. While in long term some side effects could subside,
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it is also possible that eventually more side effects will be reported. Therefore,
it is important to continue close monitoring of side effects and enquire explicitly
for any possible medication-related adverse effects.
The GLAGOV study showed a decrease in Percent Atheroma Volume (PAV)
measured by Intravascular Ultrasonography (IVUS) in patients with atheroscle-
rosis treated with PCSK9 inhibitors and statins 35. Amgen has announced that
the FOURIER trial shows a reduction in CVD outcomes in patients randomized
to evolocumab compared to placebo. However, details are currently not avail-
able 34. 
Our study has several strengths and limitations. We have developed a compre-
hensive database to describe the largest cohort of FH patients treated with
PCSK9 inhibitors outside clinical trials to date. Although our patients are treated
in a tertiary university hospital, we do consider our results representative of the
total FH population who will be candidates for PCSK9 inhibitors. However, we
report short-term results in our study. To evaluate side effects, in particular, a
larger number of patients during a prolonged treatment period is required. 
Conclusions and recommendations
We described our first clinical experience of PCSK9 inhibition in FH patients
and showed similar LDL-C reduction but more side effects compared to clinical
trials. These findings emphasize the need to establish clinical registries to mo -
nitor the long-term efficacy and side effects of PCSK9 inhibitors prescribed out-
side randomized clinical trials.
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Chapter 8
Conclusions, general discussion and
future perspective 
General discussion 
The patients we studied in chapter 3,4,5,6 and 7 were all treated at the cardio-
vascular genetics (CVG) outpatient clinic in the Erasmus MC. This outpatient
clinic is specialized in the diagnosis and treatment of inherited cardiovascular
disease (CVD) with a special focus on hereditary dyslipidemia. Patients are re-
ferred to the outpatient clinic because they, or first- or second degree relatives,
developed premature CVD and/or have dyslipidemia. The clinic is recognized
as center of expertise of vascular genetics by the Dutch Fe deration of University
Medical Centers (NFU) and is part of the European Network of Rare Metabolic
diseases 1, 2. In addition, the CVG lipid clinic is official recognized expert centre
by Landelijk Expertisecentrum Erfelijkheidsonderzoek Familiaire Hart-en
vaatziekten (LEEFH) the national expertise centre for hereditary research of fa-
milial cardiovascular disease. 
Cascade screening in the Netherlands
Between 2001 and 2014 the national Dutch cascade screening program to
 diagnose patients with familial hypercholesterolemia (FH) was executed by the
Stichting Opsporing Erfelijke Hypercholesterolemie (StOEH). This program was
financially supported by the Dutch Ministry of Public Health, Welfare and Sport.
Genetic fieldworkers approached family members of the index patient at home,
and collected clinical information and DNA blood samples. All data collected
during the course of the program, was registered in a central database. Due to
end of funding, this national cascade screening program has terminated 1-1-
2014. At that moment a total of 28.200 people with FH was identified, 42% of
the expected number of FH patients in The Netherlands 3.
Since then LEEFH is responsible for the national coordination for identifying FH
families and owner of the national FH database including information of the
pedigrees. The most important change since the termination of the national
population screening of FH, is that screening and counselling is part of regular
insured healthcare. The consequence is that the structure of screening changed
from an active to a passive form. Previously, the StOEH actively approached
people with FH to test their DNA, nowadays FH patients have to inform their
relatives to contact a healthcare provider for DNA testing. This has led to a sharp
decrease in the number of detected FH patients (figure 1). In chapter 3 we de-
scribed that even in the setting of active cascade screening, 20% children with
FH are identified because their parent experienced premature CVD. This num-
ber is likely to increase if the current trend continues, indicating that active cas-
cade screening must go on.
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Figure 1. The number of detected FH patients in the Netherlands
From Louter et al., Atherosclerosis supplements 2017 4.  
Recently a collaboration between organizations of general practitioners (GPs),
vascular internists, cardiologists and the Dutch Heart Foundation, is advocating
to renew active screening in FH patients 5. GPs are more and more becoming
aware that it is also their responsibility to identify FH in families with high cho-
lesterol (with and without CVD) especially as in clinical practice lipid levels are
often initially measured by the GP. But also dermatologists who see patients
with xanthomas or ophthalmologist who diagnose an lipoid arcus should be
aware to refer these patients to a lipid clinic. Moreover, cardiologists, neurolo-
gists and vascular surgeons must be alert of FH, especially in patients with pre-
mature CVD. In the end, screening and identification is a joint responsibility of
all health care professionals who can encounter FH patients.
The Cardio Vascular Genetic team 
The CVG team of the Erasmus MC consists of a lipidologist (internist vascular
medicine), a nurse practitioner (NP), fellows vascular medicine, a dietician and
two nurses specialized in family counselling. The team collaborates closely with
the metabolic paediatrician and cardiologists. Patients are treated by the in-
ternist vascular medicine, NP, or one of the fellows vascular medicine. Currently
the team has 5 outpatient clinics per week.
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Family based approach
The aim of this lipid clinic is to detect and treat people with CVD or inherited
lipid disorders at a young age, therefore we advocate a family based approach.
When an inherited cause of cardiovascular disease or dyslipidemia is suspected,
family counselling is offered by specialized nurses. Treatment is not limited to
the patient, but extends to the whole family. Based on this information, pedi-
grees are made, DNA analyses are performed and results are discussed in the
team. Once per week, the whole team has a simultaneous outpatient clinic. Pa-
tients can visit multiple members of the team and referral between the team
members takes place regularly. Primarily the paediatrician metabolic diseases
of the Sophia Children's Hospital treats the children with inherited dyslipi-
daemias. However, the treating internist also treats children with FH who do not
have any comorbidities. Therefore, parents and their children can choose to visit
the children's hospital or can combine their appointment at the Erasmus MC
outpatient CVG clinic. Our nurses who are specialized in family counselling work
both at the outpatient clinics as at the Sophia and Erasmus MC. 
Value based health care
In 2015, the CVG team started a project to define value-based care for FH pa-
tients. The aim was to organize a care system adding as much value as possible
to the treatment of FH patients. In collaboration with FH patients and the Hart-
en Vaatgroep, relevant measurement outcomes have been determined to mo -
nitor evidence-based treatment and counselling of patients (personalized
healthcare). Using these outcomes, it will be possible to measure and if neces-
sary, improve results of cure and care. Outcome measurements are based on
international guidelines and the long term goal is to compare the results of
treatment with other centres, but also with other countries in the future. This
will enable healthcare professionals to learn from each other and to improve
the quality of healthcare.
Prior to the visit of the out-patient clinic, patients are send digital validated
questionnaires; a quality of life questionnaire, (EQ-5D-5L, Dutch version), a med-
ication adherence questionnaire (MARS5), a FH knowledge questionnaire and
a self-efficacy and motivation questionnaire. The treating physician and NP pre-
pare and interpret the answers of the questionnaires and discuss these with the
patients during consultation. All results of the questionnaires are collected in a
database.
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Management of patients with familial hypercholesterolemia
Patients with FH are treated according to recommendations of the European
guideline for the management of dyslipidaemias 6. Treatment is life-long and
consists of two main components: lipid lowering therapy (LLT) and lifestyle mo -
dification. Healthcare providers focus on an integrated approach; medical treat-
ment and lifestyle intervention by promoting self-management. 
Promoting self-management 
LLT is considered the cornerstone of treatment of FH patients. Therefore good
adherence is essential (chapter 5). This means using medication according to
the prescription. In addition, adults and children with a hereditary dyslipidemia
are advised to live healthy, to eat healthy, to exercise sufficiently, to maintain a
healthy weight and the most important life style advice: to avoid smoking. This
health behaviour can be considered as self-management. 
In our team, the NP is specifically trained in supporting self-management in FH
patients. It is the most essential part of nursing chronically ill people 7. Self-man-
agement has many descriptions but Barlow, who is considered an expert in the
field, explained that there is no golden standard. The definition can be de-
scribed as the individual ability to deal with symptoms, treatment, physical and
psychosocial consequences and lifestyle changes inherent to live with a chronic
condition 8. Providing knowledge about the disorder is necessary for adequate
self-management, however knowledge alone is not enough. By clarifying be-
haviour of patients (insight), understanding and awareness can be created. This
is the first step of behavioural change for a healthy lifestyle. Self-efficacy and
motivation are important factors in this process. A high level of self-efficacy and
motivation is supportive in changing behaviour 9. 
Knowledge
To promote knowledge, the CVG team organizes educational meetings for pa-
tients and their relatives about FH, cardiovascular risk factors, lifestyle modifi-
cation and new developments in treatment modalities. Patients are invited as
expert speakers to share their experiences. Another way of providing know -
ledge are the posters which our team have developed and are shown in the
waiting room of the out-patient clinic, depicting targets for lipid levels, blood
pressure, weight, importance of not smoking, eating healthy and doing regular
exercise. 
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Motivation and self-efﬁcacy
The level of motivation and self-efficacy is measured by specific questionnaires.
Motivation and self-efficacy can be influenced by interventions of the treating
healthcare professionals, for example by creating realistic behavioural goals and
complimenting all positive aspects regarding achieved results of lifestyle im-
provement. But also by supporting patients to learn from each other and to or-
ganize social support from relatives 10. Finally, to promote and influence the
level of self-efficacy and motivation, positive feedback is given when lipid levels,
blood pressure, weight or medication adherence have improved. Laboratory
results as well as blood pressure and BMI are printed, discussed and handed to
the patients to take home. It is Important that the patient is in the lead, together
with the healthcare provider achievable goals are discussed and agreements
for future goals are made. To stimulate patients to improve their lifestyle it is
necessary to ensure that follow-up is provided. The treatment is based on the
relationship of the healthcare provider with the patient and his/her relatives,
with respect for autonomy. In this way, care and cure are integrated from pa-
tients’ perspective. 
Self-management in children with familial hypercholesterolemia
Although there are different points of view about the exact age of starting treat-
ment with lipid lowering medication in children with FH, it is well established
that the process of atherosclerosis begins in early childhood 11. In agreement
with the European consensus for management of children with FH, the CVG
team of the Erasmus MC prefers to perform genetic testing and if necessary
treat children with LLT before the age of 10 years if one of the parents is diag-
nosed with FH 12. The background of treating FH children before the age of 10
has two main reasons. First to start stimulating a healthy lifestyle at a young age
and second to measure lipid levels to timely start lipid lowering treatment to
delay the process of atherosclerosis 13.
Promoting a healthy life style in children
Maintaining a healthy lifestyle is not always easy for young FH patients. They
are exposed to all kinds of temptations such as smoking, drinking alcohol, un-
safe sex and unhealthy diet. When children smoke between the age of 14 and
20 years, it is very difficult for them to quit this addiction 14. At this age, smoking
behaviour is mostly influenced by peers while the influence of their parents de-
creases significantly 15. On the other hand, young children between 8-12 years
old, still have a negative attitude towards smoking. They describe smoking as
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“dirty” and “unhealthy”. This attitude needs to be strengthened by explaining
young people why the combination of smoking and FH enhances cardiovascular
risk 16. Healthcare professionals can help children to make a proper risk assess-
ment of behaviour. By giving understandable tailored information about smo -
king in order to reinforce the natural negative attitude concerning this
behaviour. Not only the disadvantages of smoking, but also the advantages of
healthy behaviour, such as sports and maintaining a healthy weight and diet,
need to be discussed 17. In addition, before children go to high school, they
must be able to resist influences from their environment. Children need to have
enough self-confidence (self-efficacy) to say “no” to friends offering cigarettes
by developing their own opinion and identity on this topic. A high degree of
self-efficacy is necessary to change behaviour, for example the intention to avoid
or stop smoking 9. It is custom in our outpatient clinic to make an agreement
not to start smoking between the child and the treating healthcare professional
at the end of each appointment. In the end: prevention is always better than
cure. 
Self-management in adults with familial hypercholesterolemia
Since a few decades, statins are the first choice treatment for patients with FH.
LLT by statins is effective in lowering LDL-C levels. CVD risk has decreased sub-
stantially since statin treatment became available, but despite maximum treatment
for many years, 12% of patients still develop CVD (chapter 4). This is noteworthy
because in our clinic 90% of the patient use maximally tolerated lipid lowering
therapy: almost two-thirds of the adult FH population (61%) at our outpatient lipid
clinic are currently treated optimally with statins, 29% uses maximum tolerated LLT
because of side effects. We showed that those patients who still develop CVD,
are not patients with as only risk factor LDL-C levels not on target, but especially
those patients who have other risk factors such as smoking or hypertension have
an increased risk of CVD (chapter 4). The question is if more potent lipid lowering
medication, such as Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors,
will be the solution for abolishing cardiovascular risk. 
Investment in lifestyle modiﬁcation 
Patients and healthcare professionals should invest more in lifestyle modifica-
tion. There is still much to be gained in investing in a healthy lifestyle, such as
quit smoking- or even better smoking prevention- than increasing medication.
Recently Kehra, et al., showed that a healthy lifestyle in patients with a geneti-
cally increased CAD risk was associated with a nearly 50% lower relative risk of
Conclusions, general discussion and future perspective 
119
CAD compared to an unfavourable lifestyle 18. Chow et al., showed in a ran-
domized lifestyle intervention study in CAD patients that adherence to diet,
physical activity, and smoking cessation was associated with a decreased risk of
cardiovascular events. Those who reported persistent smoking and non-adher-
ence to diet and exercise had a nearly 4-fold increased risk of myocardial infarc-
tion/stroke/death compared to never-smokers who modified diet and exercise
19. However, achieving optimal health behaviour is a challenge for both patients
and healthcare professionals. Smoking is a major avoidable risk factor. The most
effective treatment to stop smoking is a combination therapy of intensive inter-
vention of pharmacotherapy and behavioural support 20. However, the most im-
portant part consist of motivation to stop smoking. Healthcare providers should
investigate more time in this first step of therapy, not only by communicating
that patient must stop smoking. Personalized goals to quit smoking need to be
investigated and discussed. 
The results of the specialized stop smoking outpatient clinic of the Erasmus MC
showed comparable outcomes to stop smoking methods used in randomized
trials 21. Although 23% did not resume smoking after one year, the results of
smoking cessation in general are not very successful. However, lifestyle modifi-
cation remains essential to improve patients’ cardiovascular outcome. There-
fore, treatment of FH patients should not only focus on optimizing LDL-C levels,
but also on improving other CVD risk factors (chapter 4).
Medication adherence
FH patients have a chronic condition, they have to live with FH the rest of their
life. They don’t have any physical symptoms, but need to take preventive med-
ication life-long. Only 19% of our FH patients, achieved their LDL-C treatment
goal. We assessed whether non-adherence and factors associated with non-ad-
herence in chapter 5. Non-adherence of statins was reported in 11% of the pa-
tients. Those patients who were non-adherent, were younger and used statins
more recently than those who were adherent. Moreover, they showed higher
levels of treated LDL-C-and total cholesterol and had a lower untreated baseline
total cholesterol 22. Especially young people (18-35 years old) found it difficult
to use medication daily. They have to do something (daily intake of medication)
for their future, while they don’t have any symptoms at this moment. In addition,
medication adherence is not static but a continuous life-long process 23. There-
fore, during every visit patients should be asked about their medication intake
without judgement. We developed a risk score based on age and lipid values
which can help to assess the risk of non-adherence (chapter 5). The cause of
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non-adherence varies and has to established individually. There is no standard
solution for this problem. Individual causes for non-adherence such as the level
of health literacy, developing skills to take responsibility or to think abstractly,
have to be established and to discussed together with the patient to find a tai-
lored suitable solution 24.
New medication; Proprotein Convertase Subtilisin/Kexin 9 inhibitors
PCSK9 inhibitors are reimbursed in the Netherlands since 2016. Currently two
PCSK9 inhibitors are available; evolocumab (140 mg sc once per 2 weeks or 420
mg once per 4 weeks for homozygous FH patients) and alirocumab (75 mg or
150 mg sc once per 2 weeks). PCSK9 inhibitors are associated with impressive
LDL-C reductions and a favourable safety profile 25,26. The Further Cardiovas-
cular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
(FOURIER) study showed a mean LDL-C reduction of 59% and a 15% reduction
in CVD events in high risk CVD patients using evolocumab 140 mg per 2 weeks
or 420 mg per 4 weeks compared to placebo 27.
PCSk9 inhibitors are currently reimbursed for patients at very high risk of CVD
who do not reach LDL-C treatment targets despite maximum tolerated LLT. FH
patients are considered to belong to this category Homozygous FH patients
who carry two LDLR negative mutations are not suited for this therapy as resid-
ual LDLR activity is mandatory for its effect. Maximum tolerated LLT also applies
for heFH patients with documented statin intolerance defined as statin-associ-
ated myalgia for at least three different statins in accordance with the flow chart
described by EAS/ESC consensus who use ezetimibe monotherapy 28. We show
that heFH patients who use a PCSK9 inhibitor in combination with statin and
ezetimbe show similar decreases in LDL-C compared to clinical trials (chapter 7).
At baseline, only 19% of FH patients achieved the LDL-C target (LDL-C ≤2.5
mmol/l for primary prevention or LDL-C ≤1.8 mmol/l for secondary prevention),
with the addition of a PCSK9 inhibitor the percentage of patients reaching LDL-
C target increased to 58% (chapter 7). FH patients in our cohort showed large
variation in LDL-C decrease, ranging from 10% to 90%. An additional analysis
between the hypo responders and hyper responders (≤25% - ≥75% decrease)
showed that LDL-C decrease was larger in FH patients without known genetic
mutations compared to FH patients with a known pathogenic mutations. An ex-
planation for this finding could be the reduced residual function of LDL recep-
tors in FH patients with a genetic mutation. Another possible explanation for
this variation could be the PCSK9 level in patients. If patients have higher PCSK9
levels , more PCSK9 can be bound, possibly resulting in a more pronounced
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LDL-C decrease. Future studies measuring PCSK9 levels will establish if this hy-
pothesis is true.
Promoting self-management and PCSK9 inhibitors
Initially we had concerns about lifestyle adherence in patients who started with
PCSK9 inhibitors. The impressive decrease in LDL-C levels could potentially
negatively affect the maintenance of a healthy lifestyle. However patients were
re-encouraged to investigate in lifestyle-modification. A few patients quit smok-
ing after 30 years, some performed a higher level of exercise and others focused
more on a healthy diet or on medication adherence, demonstrating that moti-
vation of patients to change their behaviour is not a fixed situation. Despite the
impressive decrease in LDL-C as a result of PCSK9 inhibitor therapy, not all pa-
tients achieved target levels. The mean BMI in our FH population was 27.3±4.0
kg/m2. Being overweight was not associated with not achieving treatment goals.
However lifestyle modification should persistently be integrated in the treat-
ment of FH patients (chapter 7). 
All patients who start with a PCSK9 inhibitor are invited for a group consultation
led by the NP. Prior to the first subcutaneous injection of the PCSK9 inhibitor,
patients and their relatives receive information how this new drug works and
get instructions how to administer this auto-injector. In addition patients are ed-
ucated to continue all current medication and to maintain a healthy lifestyle,
practical issues such as vacations and adherence to this unusual administration
schedule are addressed.
A new experience; how low can you go?
PCSK9 inhibitor regiment pose healthcare professionals and patients for new
challenges: namely the very low LDL-C levels which can be achieved. Seventeen
percent of the patients who started with a PCSK9 inhibitor reached LDL-C levels
of <1.0 mmol/l) (chapter 7). Currently it is not known whether a threshold exist
below which further LDL-C reduction is not beneficial anymore or can even be
harmful. Therefore, in some patients with LDL-C levels <0.6 mmol/l the decision
was made to reduce the dose or increase the interval of the PCSK9 inhibitor.
Blom et al., showed that in patients using evolocumab vitamin e and steroid
levels are not reduced even in patients who reach LDL-C levels <0.4 mmol/L.
As in the near future many patients who use PCSK9 inhibitors will encounter
very low LDL-C levels, close monitoring for instance via a registry will be impor-
tant to assess long term effects 29.
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Adverse drug reactions of lipid lowering therapy 
In our experience we found slightly more side effects attributed to PCSK9 in-
hibitors in clinical practice compared to clinical trials (chapter 7). There were no
differences in side effects between men and women. In particular, neurological
side effects were a reason for stopping PCSK9 inhibitors. Initially a minimal but
significant increase in neurocognitive side effects was reported in a meta-analy-
sis of all PCSK9 inhibitor trials 30. However, the EBBINGHAUS study (Evaluating
PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular
Risk Subjects) showed that there was no association between the cognitive func-
tion of patients with a cardiovascular event and the use of a PCSK9 inhibitor 31.
Our patients also experienced more symptoms of flu-like symptoms and ab-
dominal complaints. A reason for this overrepresentation of side effects could
be the fact that all patients were informed about side effects of this medication
prior to the first administration 32. At present, patients use internet and search
for information more often. It should be noted that all complaints have been
reported by the patients themselves and in some patients it was uncertain if the
reported side effects were associated with the PCSK9 inhibitors. In collaboration
with the Landelijke registratie evaluatie bijwerkingen (Lareb), the Dutch Phar-
macovigilance and knowledge centre for adverse drug reactions, we will con-
tinue to monitor possible adverse drug reactions carefully.
We did find gender differences in side effects of statin therapy (chapter 6).
While there was no gender difference in the overall percentage of patients who
reported any side effect, women were more likely to report having experienced
three or more side effects. Also a larger proportion of them reported severe im-
pact of statin therapy on their quality of life. However, women received less
often maximum statin therapy compared to men (chapter 6). Because side ef-
fects might influence adherence to treatment, it is important to address this
issue regularly as health care provider. 
Future perspective
New guideline for patients with FH
Currently a guideline committee has developed a new national multidisciplinary
guideline on dyslipidemia with a focus on FH, which describes how to detect
and treat those people and their first and second degree relatives. Often the
general cardiovascular risk Management (CVRM) guideline is incorrectly utilized
in these patients, resulting in insufficient or no treatment at all of FH patients.
This general guideline for cardiovascular disease prevention is not applicable
to patients with hereditary dyslipidemia because the absolute risk is higher than
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the population risk chart (SCORE) used in the guideline 33. Collectively, cardiol-
ogists, the paediatricians, the internists and GPs are involved in the detection
and treatment of people with FH. The ultimate aim is to maintain the quality
and efficacy of FH care in The Netherlands and the expectation is that the new
guideline will be able to help to achieve this goal. 
Medication adherence in children
Children up to 18 years have not been examined in our study assessing adher-
ence to lipid lowering medication (chapter 5). Children who have other chronic
disorders, such as asthma or diabetes mellitus type 2, show a high percentage
of non-adherence. The percentage of medication adherence in chronically ill
children with the above mentioned disease varies, but the adherence is pre-
dominantly low. Adherence of medication decreases as the age increases 34, 35.
Adolescence is a strong predictor of non-adherence. Many factors are associ-
ated with non-adherence in children 24. Importantly, there is a clear relationship
between non-adherence and poor outcome of disorders described in literature
36. Successful interventions to improve medication adherence in children are
not available 37. In case of unconsciously forgotten medication, sending text
messages seems to be effective. But when medication is not used consciously,
this intervention will not work. Therefore, improving medication adherence and
discovering factors associated with non-adherence in children remains an im-
portant topic for the optimal treatment of children 38.
Collaboration with other partners
In the near future, the cardiovascular center will be established in the Erasmus
MC in collaboration with the department of cardiology, internal medicine, tho-
rax surgery and vascular surgery. One of the focuses will be an integrated ap-
proach focused on secondary prevention coordinated by nurses. These CVD
prevention programs, in particular in up-titration of medication, have proven to
be successful 39. Lipid levels and blood pressure were more often on target in
CVD patients after intervention of a nurse, although the impact on lifestyle risk
factors remained limited. Collaboration with other partners in coaching of
weight control by Weight Watchers, stop smoking by trained professionals and
developing instruments for a more physical active lifestyle by Philips DirectLife
seems to be effective 40. To improve cardiovascular risk management according
to guidelines, healthcare professionals and patients are advised to cooperate
with these new partners in healthcare. 
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Chapter 9
Summary/Samenvatting
Familial hypercholesterolemia (FH), is an autosomal dominant disorder of the
lipid metabolism with a prevalence of 1:244 in The Netherlands. FH is caused
by pathogenic mutations in the low-density lipoprotein receptor (LDLR),
Apolipoprotein B (APOB) or PCSK9 gene and characterized by high levels of
LDL-Cholesterol (LDL-C) leading to high/severe risk of cardiovascular disease
(CVD) at premature age. Prevention of CVD consist of the combination of lipid-
lowering therapy and lifestyle modification. 
In this thesis, we studied several parts of the management of patients with FH.
In the first part of this thesis we studied the diagnosis and risk prediction of pa-
tients with FH.
Chapter 2 describes the usefulness and necessity of lipid testing. Why should
we test lipids, who should we test according the guidelines and when should
we test lipids. Important to every clinician should be the question: What do the
results mean to my patient? A systematic risk stratification to identify those at
the highest risk is required. European, British and American guidelines are all
based on a risk calculator but differ in their recommendations concerning lipid
testing. What they have in common is that they advocate an integrated ap-
proach with the engagement of the patient as a partner in cardiovascular dis-
ease (CVD) prevention. Nonetheless, despite all guidelines, in the end decisions
concerning lipid testing are about communication with the patient involving in-
dividual circumstances including why, who and when.
Chapter 3 describes the setting of cascade screening of patients with FH in The
Netherlands and specially the screening of children with FH. The national cas-
cade screening programme has terminated at the end of 2013. This study re-
ports that 1:5 children with FH are identified because their parent experienced
CVD, mostly at a premature age. The fact that CVD is still a presenting event of
FH in especially fathers, shows that nationwide screening might have been ter-
minated too early. To prevent CVD, the next generation should be in clinical at-
tention to start statin treatment and a healthy lifestyle in time.
Chapter 4 describes that despite effective treatment with optimal lipid lowering
treatment (LLT) patients with FH still develop CVD. We showed that 12% of pa-
tients still develop CVD and identified individuals at high risk in a cohort of 821
heterozygous adult FH patients using long time LLT. We demonstrated that the
residual risk of cardiovascular events consist of 16 events per 1000 statin-treated
person years. Almost one third of those patients with a cardiovascular event,
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developed a subsequent event, underlining the need for CVD prevention in this
population. In addition to lipid parameters, classical risk factors, especially
smoking and hypertension, contributed to the developing of cardiovascular
events during LLT. Therefore, treatment of FH patients should not only focus
upon optimizing LDL-C levels, but also on improving other CVD risk factors.
In the second part of this thesis, the management of patients with FH is de-
scribed.
Chapter 5 describes the development of a prediction model to identify non-
adherent FH patients. The results of this study demonstrate that statins reduced
the untreated total cholesterol level by 46% in our heterozygous FH study pop-
ulation. In only 19% of patients the treatment goal was achieved. We assessed
whether these results were influenced by the factor of non-adherence. Non-ad-
herence of statins was reported in 11% of the patients. They were younger and
shorter on statin prescription. They showed higher treated LDL- and total cho-
lesterol levels and had a lower untreated baseline cholesterol. Based on these
independent variables, a non-adherence risk score calculator was developed to
assess and improve adherence in clinical practice during patient consultation.
Chapter 6 reported gender differences in lipid profile, lipid lowering therapy,
statin adverse effects, and factors associated with treatment effectiveness in a
well-defined cohort of patients with FH. This study highlights the lower likeli-
hood for women to receive high-intensity therapy despite their poorer baseline
lipid profile and emphasizes the negative impact of statin side effects on achiev-
ing the desirable clinical outcomes among women.
Chapter 7 described the first clinical experience of a recently new class of lipid-
lowering therapy; Proprotein Convertase Subtilisin / Kexin 9 (PCSK9) inhibitors
in FH patients. Outside clinical trials the efficacy and side effects of PCSK9 in-
hibitors is evaluated and showed similar LDL-C reduction but more side effects
and injection site reactions compared to clinical trials in FH patients.
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Familiaire hypercholesterolemie (erfelijk verhoogd cholesterol, FH), is een au-
tosomaal dominante afwijking van het lipidenmetabolisme en komt bij 1:244
mensen in Nederland voor. FH wordt veroorzaakt door pathogene mutaties in
de low-density lipoprotein (LDL) cholesterol receptor, Apolipoprotein B (APOB)
of het Proprotein convertase subtilisin/kexin 9 (PCSK9) gen. Deze aandoening
wordt gekenmerkt door hoge LDL-Cholesterol waarden vanaf de geboorte en
leidt onbehandeld tot een hoog risico van hart-en vaatziekten op jonge leeftijd.
Preventie van hart-en vaatziekten bij deze mensen bestaat uit een combinatie
van lipidenverlagende medicatie en leefstijlaanpassingen. 
In deze thesis, zijn verschillende onderdelen van management van zowel de
medische behandeling als de verpleegkundige zorg van FH patiënten
bestudeerd. In het eerste onderdeel werd het stellen van de diagnose FH en
het voorspellen van risico’s bij FH patiënten bestudeerd.
Hoofdstuk 2 beschrijft het nut en de noodzaak van het testen van een lipiden-
profiel. Waarom zouden we lipiden moeten testen, wie zouden volgens de richtli-
jnen hun lipiden moeten laten testen en wanneer zou iemand zijn lipidenwaarden
moeten laten testen. De belangrijke vraag voor elke behandelaar moet steeds
zijn; wat leveren de resultaten op voor mijn patiënt? Een systematische risico-strat-
ificatie is vereist om juist degenen met het hoogste risico te kunnen identificeren.
Europese, Britse en Amerikaanse richtlijnen zijn allemaal gebaseerd op een risi-
coberekening, maar verschillen in hun aanbevelingen voor het testen van lipiden.
Wat zij gemeen hebben, is dat zij een geïntegreerde aanpak bepleiten waarbij de
betrokkenheid van de patiënt als partner in preventie van hart- en vaatziekten
voorop staat. Toch, ondanks alle richtlijnen, beslissingen met betrekking tot het
testen van lipiden worden genomen op basis van communicatie met de patiënt
gebaseerd op individuele omstandigheden, waaronder waarom, wie en wanneer.
Hoofdstuk 3 beschrijft de achtergrond van de cascade-screening van patiënten
met FH in Nederland en speciaal de screening van kinderen met FH. Het na-
tionale cascade screening programma is eind 2013 afgesloten. Deze studie ver-
meldt dat 1:5 kinderen met FH wordt geïdentificeerd omdat hun ouders hart-en
vaatziekten hebben doorgemaakt, meestal op premature leeftijd. Het feit dat
hart-en vaatziekten zich nog steeds voordoet in vooral vaders met FH, veron-
derstelt dat het landelijke screeningsprogramma mogelijk te vroeg is beëindigd.
Om hart-en vaatziekten te voorkomen, dient de volgende generatie op tijd in
beeld te worden gebracht om de behandeling met statines en een gezonde
leefstijl tijdig te kunnen starten.
Chapter 9
132
Hoofdstuk 4 beschrijft de uitkomsten van een effectieve behandeling voor
lange tijd met stabiele lipidenverlagende medicatie bij patiënten met FH. In
een cohort van 821 heterozygote volwassen FH patiënten is onderzocht hoeveel
patiënten hart-en vaatziekten ontwikkelen, daarnaast is gekeken welke risico-
factoren daarop van invloed zijn. We hebben aangetoond dat het resterende
risico op het verkrijgen van cardiovasculaire gebeurtenissen 12% is (16 events
per 1000 statine behandelde persoons jaren). Bijna een derde van deze patiën-
ten met een cardiovasculair event ontwikkelde een tweede event, daarmee
werd de noodzaak van hart-en vaatziekten preventie in deze populatie nog
meer onderbouwd. Naast lipidenparameters, dragen klassieke risicofactoren
als roken en hypertensie, bij aan de ontwikkeling van hart-en vaatziekten tijdens
lipidenverlagende therapie. Daarom dient de behandeling van FH-patiënten
zich niet alleen te richten op het optimaliseren van het LDL-Cholesterol, maar
ook op het verbeteren van overige risicofactoren van hart-en vaatziekten.
In het tweede deel van dit proefschrift wordt het management van patiënten
met FH beschreven.
Hoofdstuk 5 beschrijft de ontwikkeling van een voorspellingsmodel om niet-ther-
apietrouwe FH patiënten te identificeren. De resultaten van deze studie laten zien
dat statines het onbehandelde totale cholesterol met 46% verlaagd in deze het-
erozygote FH studie populatie. Bij slechts 19% van de patiënten werd het behan-
deldoel LDL-C ≤2.5 mmol/l bereikt. We hebben onderzocht of het niet trouw
innemen van de medicatie van invloed was op het bereiken van deze streefwaarde.
Therapie-ontrouw van statines werd gerapporteerd in 11% van de patiënten. Ze
waren jonger en gebruikten korter een statine. Zij toonden hogere behandelde
LDL-en totaal cholesterolwaarden en hadden een lager onbehandeld baseline
cholesterol. Op basis van deze onafhankelijke variabelen is een risicoscore calcu-
lator voor therapie-ontrouw ontwikkeld om in de klinische praktijk therapie-on-
trouw beter te kunnen beoordelen en daar waar mogelijk te verbeteren.
Hoofdstuk 6 rapporteert in een goed gedefinieerd cohort van patiënten met
FH verschillen tussen mannen vrouwen in het lipidenprofiel, de lipidenverla-
gende therapie, bijwerkingen van statines en factoren geassocieerd met de ef-
fectiviteit van de behandeling. Deze studie toont aan dat vrouwen minder vaak
hoge doseringen statinetherapie krijgen voorgeschreven ondanks hun hogere
onbehandelde lipidenwaarden in vergelijking tot mannen. Tevens wordt de
negatieve impact van bijwerkingen van statines op het bereiken van het gewen-
ste klinische resultaat onder vrouwen benadrukt.
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Hoofdstuk 7 beschrijft de eerste klinische ervaring van een nieuwe klasse lipi-
den verlagende therapie; Proprotein Convertase Subtilisin / Kexin 9 (PCSK9)
remmers bij FH patiënten. Buiten klinische studies is de werkzaamheid en de
bijwerkingen van PCSK9-remmers geëvalueerd. Deze FH patiënten lieten een
vergelijkbare LDL-C reductie zien maar vertoonden meer bijwerkingen en in-
jectie reacties vergeleken met de klinische studies.
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1. PhD training
Research skills
Methodology of research and preparation of grant applications.
Course critical reading of articles.
Statistics and Survival Analysis for MD.
Basic Introduction Course SPSS.
GCP registration (BROK) course.
International Presentations
Spring Meeting, ESC; An example of a nurse led lipid clinic, Sweden.   
Cardiovascular Nursing in the Netherlands, Athene.                
Annual congress ESC; Predicting adherence of FH patients, Paris.                                
Patients with FH in the Netherlands, Houston. 
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Euro Prevent; Residual cardiovascular risk in FH patients, Malaga.   
Euro Prevent; PCSK/9 inhibition in patients with FH, Malaga.       
Euro Heart Care; Residual cardiovascular risk in FH patients, Sweden.
Euro Heart Care; PCSK/9 inhibition in patients with FH, Sweden.     
Wetenschapsdagen; Residual cardiovascular risk in FH patients, Belgie
National Presentations
Annual congress V&VN VS; Workshop about cholesterol.           
Annual congress V&VN VS; Residual cardiovascular risk.
CarVasZ; Cascade screening must go on.   
Nationale lipidendag PCSK9 remming: De eerste Nederlandse ervaringen.                      
CarVasZ; Residual cardiovascular risk in FH patients.               
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Annual congress ESC, Amsterdam.
Annual congress ESC, Barcelona.
Annual congress V&VN VS.
Annual congress V&VN VS.
Annual congress V&VN VS.
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Coeur course Cardiovascular imaging and diagnostics.
Year 
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2010
2015
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2008
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2013
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2017
2017
2017
2017
2017
2015
2016
2015
2016
2016
2017
2017
2017
2017
2011
2013
2014
2014
2015
2016
2016
2017
Hrs/ECTS
1
1
1
1
1
Total 5
1
1
1
1
1
0.5
0.5
0.5
0.5
Total 7
1
1
1
0.5
1
1
0.5
0.5
0.5
Total 14
1
1
1
0.6
0.6
0.6
0.9
0.5
Total 6.2
Chapter 10
140
2. Teaching activities
University of applied sciences Rotterdam 
Promoting self-management 
Teaching patients how to use PCSK9 inhibition
Lecturing
Lectures at meetings for FH patients and caregivers
Supervision
Nurse teacher of MANP student
Other
President of the Dutch National Society of Cardiovascular 
Nursing (NVHVV).
Board member of the Dutch National Society of Cardiovascular
Nursing.
Board member The National Society committee of the Council
Cardiovascular Nurses and Allied Professions (CCNAP) of the
ESC. 
Board member of the Accreditation Committee NVHVV.
President of the expert group of Nurse Practitioners NVHVV.
President of nurse practitioners and physician assistants section
of the Erasmus MC. 
Professional membership
Dutch National Society of Cardiovascular Nursing (NVHVV).
Dutch Society of Nurse specialists (V&VN-VS).
The Union (NU’91).
Council of Cardiovascular Nurses and Allied Professions
(CCNAP) of European Society of Cardiology (ESC).
Year 
2014-2015
2015-2017
2009-2015
2014
2005-2008
2008-2011
2007-2009
2010-2015
2013-2016
2015-present
Hrs/ECTS
1
0.5
1
0.5
Total 3
3
2
1
2
1
1
Total 10
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Tenslotte wil ik een aantal mensen bedanken die mij hebben geholpen en
 bijgestaan bij het tot stand komen van dit proefschrift, om te beginnen met:
Prof. dr. J.L.C.M. van Saase, mijn promotor, beste Jan, veel dank voor het
gestelde vertrouwen en ik vind het een eer dat het hoofd van de afdeling in-
wendige geneeskunde mijn promotor is. Met name in de lastige laatste fase
van het voltooien van mijn proefschrift heb ik je steun zeer gewaardeerd. 
Dr. J.E. Roeters van Lennep, mijn copromotor, beste Jeanine, wat een enthou-
siasme en drive schuilt er in jou. De reden dat mijn promotie zo voorspoedig is
voorlopen is daarvan het gevolg. Jij hebt mij veel kansen geboden. Heel veel
dank voor je vertrouwen en geduld met mij. Ik moest nog veel leren in het ver-
richten en uitvoeren van onderzoek en op een respectvolle manier heb jij dat
weten over te dragen. Dat is een hele mooie eigenschap die je moet koesteren. 
Dr. M.J. lenzen, mijn andere copromotor, beste Mattie, door jou ben ik steeds sys-
tematischer gaan werken. Elke keer weer informeerde je naar mijn syntaxen en
systematiek. Dank ook voor je ondersteuning van de statistische analyses. Jouw
kritische maar ook verpleegkundige blik leverde vaak weer een andere kijk op het
onderzoek. De insteek van dit proefschrift moest vooral een mix worden van
medische en verpleegkundige aspecten in de zorg rondom patiënten met famil-
iaire hypercholesterolemie, ik vind dat het goed gelukt is. 
De leden van de kleine commissie bestaande uit Prof. dr. W.J.M. Scholte op
Reimer, Prof. dr. H.O. Franco en Prof. dr. F. Zijlstra, wil ik hartelijk danken voor het
aandachtig lezen van mijn proefschrift en de beoordeling daarvan. De overige
leden van de commissie; Prof. dr. F.L.J. Visseren. Prof. dr. H.J.M. Verhagen en Prof.
dr. M. van Dijk wil ik bedanken voor het plaatsnemen in de grote commissie. 
Bert Hoogeveen wil ik bedanken voor het ontwerpen van het omslag en het
opmaken van dit boek.
Dan mijn paranimfen Margriet en Jorie: 
Margriet, mijn lieve vriendin en sportmaatje 3 keer per week, voordat dit boek
uitkwam kende jij de inhoud al. Het hele traject met voor-en tegenspoed heb
jij op de voet gevolgd. Jij hebt me gesteund door dik en dun en mijn geklaag
en vreugde aangehoord tijdens al onze trainingen. Samen hebben we 4
marathons gelopen waaronder New York in de tijd van de verkiezingen van
Obama, “Yes we can, ervaringen voor het leven”. Niet voor niets ben jij dan
ook mijn paranimf. Ik hoop op nog vele jaren vriendschap en samen sporten.
Jorie, mijn fijne vriendelijke collega, medeauteur en atletiekfan. Altijd weer be-
langstellend naar mijn onderzoek en voortgang in het proces. We delen
dezelfde passie voor atletiek, direct online bij wedstrijden op de televisie of
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samen naar een Europees kampioenschap. Misschien nog samen naar Berlijn?
Toch jammer dat je de marathon van Rotterdam net 2 minuten sneller hebt
gelopen dan ik.
Medeauteurs en ondersteuners van de artikelen: Janneke, Eric, Sophie, Fre -
derique, Sven, Merijn, Ron, Tatyana, Monique, Maryam, Ada en Henk, dank voor
jullie inzet en support. In het bijzonder veel dank aan Janneke Langendonk, jij
hebt mij de grondbeginselen van het verrichten van onderzoek  bijgebracht.
Zonder enige ervaring en opleiding begon ik aan dit traject, jij hebt mij de weg
gewezen hoe te starten in een dergelijk traject. Dank voor je inzet en
vertrouwen.
Hanny, Joy en Kim mijn kamergenoten wil ik bedanken voor hun belangstelling,
collegialiteit en begrip de afgelopen jaren. Jullie vervullen een belangrijke en
waardevolle positie binnen ons cardiovasculair genetica team.
Het bestuur en collega’s van de vakgroep verpleegkundig specialisten van het
Erasmus MC; Judith, Mirjam Monique, Lianne, Anita en Marit wil ik bedanken
voor hun steun en begrip tijdens dit proces. Ook collega’s uit mijn intercollegiale
toetsing groep; Judith, Marit, Margot en Martie, dank voor jullie betrokkenheid.
Collega’s van de cardiologie; Paul en Marja ook aan jullie dank voor jullie be-
trokkenheid. Na mijn promotie wil ik meer tijd besteden aan de positionering
van de verpleegkundig specialist (VS) in het Erasmus MC. Ik hoop een voor-
beeld te kunnen zijn voor collega’s die een promotietraject overwegen. We
hebben een inhaalslag te maken, evidence based care by nurses, onze professie
heeft jullie nodig!
Mijn studiegenoten van de Master Advanced Nursing Practice (MANP) opleid-
ing en in het bijzonder Judith, Henk, Monique en Tineke, dank voor de support
en gezellige uren van relativering en wijn in café Ari. Hopelijk spreken we snel
weer af, het is weer de hoogste tijd.
Mijn leidinggevende Mieke; dank voor je oprechte belangstelling en steun. Col-
lega’s van de polikliniek; Marjolein, Grace, Kader, Evelien, Linda, Nicole,
Marieke, Trudy, Charlene, Linda en Yvette dank voor jullie ondersteuning van
mijn spreekuren dames. Het diabetesteam; Zuzana, Elly, Jelena, Kirsten, Behiye,
Mandy, Maaike, Hanneke en Kirsten dank voor jullie interesse. Collega’s van het
laboratorium; Leonie en Evelien, dank voor jullie inzet voor het optimaal ver-
lopen van de biobank van onze patiënten. 
Vrienden en vriendinnen; Karin, Nien, Monique, Plien, Marcia, Karin, Marlies,
maar ook Ellie en Bart, Sandra en Hans, Nicolette en Marcel, Petra en Ben, Hans
en Martine, Fred en Kirsten, Karin, Mirjam, Margriet en Rob, Marcel en Nancy,
Eric en Renee, Pieter en Frederique, Meike en Eric en de fietsvrienden van
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Tjebbe en partners, ik geniet altijd met volle teugen van onze vakanties, week-
endjes weg of avonden uit. Deze waardevolle vriendschappen zorgen voor een
goede balans in mijn leven tussen inspanning en ontspanning.
Ook collega’s van de Nederlandse Vereniging voor Hart en Vaatver-
pleegkundige (NVHVV) wil ik bedanken voor hun steun; Linda Joziasse als
voorzitter, Sander, Marjolein, Corien, Ellen, Sylvia, Wilianne, Corrie, Marja en
Stan als inspirerende collega’s. Marjolein niet alleen onze promotietrajecten
deelden we samen maar ook de kamers op congressen. Dank voor veel gezel-
ligheid, steun en bijkletsen met een glaasje wijn, je bent een vriendin geworden,
ik ben er trots op jouw paranimf te mogen zijn binnenkort. 
Uiteraard wil ik ook mijn familie bedanken voor hun belangstelling; Roland en
Patricya, Leonie en Joris, Anno en Colette, Tineke, Titus en Nicole en Pa maar
in het bijzonder mijn ouders; Lieve pappa en mamma, een mooi moment om
jullie te bedanken voor alle kansen die ik van jullie in mijn leven heb gekregen.
Jullie hebben de voorwaarden geschapen voor dit hele traject en ik heb ze
benut om te studeren, eigen keuzes te maken en zelfstandig te kunnen zijn. Ik
weet dat jullie trots zijn maar dat jullie ook vaak zorgen hebben gehad om mijn
drukke bestaan. Maar lieve mam, je gaf ons zelf het voorbeeld door op je 52e
nog het VWO te volgen. Veel discipline en nooit te oud om te leren, zie hier
het resultaat. Jullie zijn nu 81 en 83 jaar oud, gezond en vitaal en nog steeds
zeer reislustig, een groot voorbeeld voor mij. Pap volgend jaar weer samen naar
een EK of een WK schaatsen?
Dan tenslotte wil ik mijn mannen bedanken; op de eerste plaats mijn aller aller-
liefste Tjebbe. Ik hou van je humor, bewonder je tolerantie en ben je dankbaar
voor je geduld en relativeringsvermogen. Het leek misschien dat ik niet altijd
naar je luisterde maar deze eigenschappen van jou hielden mij op de been in
moeilijke tijden. Inderdaad de wereld zal niet veranderen door dit proefschrift;
ik hoop echter wel nog meer van de wereld te kunnen zien en te genieten
samen met jou. We kregen samen Hidde, Jouke en Geert: “mannen ik ben trots
op wat jullie doen en wie jullie zijn geworden in het leven, ieder op z’n eigen
manier. Ik hoop dat we jullie de goede weg hebben gewezen naar een gelukkig
leven, maar ook dat doorzettingsvermogen ergens toe leidt. Ik besef me dat ik
een rijk mens ben, met jullie heb ik drie keer goud, ik houd van jullie”. 
Tenslotte nog dit: ooit heb ik gekozen voor het vak verpleegkunde aan het
HBO-V samen met Sandra, Marc, Ellen, Martin en Ab, een prachtig beroep waar
ik trots op ben en opnieuw voor zou kiezen in deze tijd. Deze nieuwe titel brengt
daar geen verandering in. Ik ben en blijf verpleegkundige (specialist).
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